

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029708
Article Type:	Protocol
Date Submitted by the Author:	07-Feb-2019
Complete List of Authors:	<p>Scott, Allison; Government of Alberta, Ministry of Health; PolicyWise for Children & Families</p> <p>Buchan, Sarah; Institute for Clinical Evaluative Sciences; Public Health Ontario</p> <p>Kwong, Jeff; Institute for Clinical Evaluative Sciences</p> <p>Drews, Steven; Alberta Provincial Laboratory for Public Health; University of Alberta, Division of Preventive Medicine</p> <p>Simmonds, Kimberley; Alberta Ministry of Health, Epidemiology and Surveillance</p> <p>Svenson, Lawrence; Government of Alberta, Ministry of Health; University of Calgary Cumming School of Medicine, Department of Community Health Sciences</p>
Keywords:	Influenza, Vaccine effectiveness, Case Control, Test-negative, Administrative data, Population-level

SCHOLARONE™
Manuscripts

1
2
3 1 **TITLE**

4
5 2 **Using population-wide administrative and laboratory data to estimate type- and subtype-specific**
6 3 **influenza vaccine effectiveness: a surveillance protocol**

7
8 4 Allison N Scott^{1,2,3}

9
10 5 Sarah A Buchan^{4,5,6}

11
12 6 Jeffrey C Kwong^{4,5,6,7,8}

13
14 7 Steven J Drews^{9,10}

15
16 8 Kimberley A Simmonds^{1,11}

17
18 9 Lawrence W Svenson^{1,11, 12, 13}

19
20
21 10

22 11 **Affiliations**

23
24 12 ¹Ministry of Health, Government of Alberta, Edmonton, AB, Canada

25
26 13 ²PolicyWise for Children & Families, Edmonton, AB, Canada

27
28 14 ³Department of Public Health, Concordia University of Edmonton, AB, Canada

29
30 15 ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

31
32 16 ⁵Public Health Ontario, Toronto, ON, Canada

33
34 17 ⁶Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

35
36 18 ⁷Department of Family & Community Medicine, University of Toronto, Toronto, ON, Canada

37
38 19 ⁸University Health Network, Toronto, ON, Canada

39
40 20 ⁹The Alberta Provincial Laboratory for Public Health, Edmonton, AB, Canada

41
42 21 ¹⁰Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada

43
44 22 ¹¹ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary,
45 23 AB, Canada

46
47 24 ¹² School of Public Health, University of Alberta, Edmonton, AB, Canada

48
49 25 ¹³ Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada

50
51
52 26

53
54 27 **Corresponding Author:**

55
56 28 Allison N. Scott, Ph.D.

1
2
3 29 PolicyWise for Children & Families
4
5 30 1000, 9925-109 Street NW
6
7 31 Edmonton, Alberta, Canada T5K 2J8
8

9 32

10
11 33 **Email Addresses**

12
13 34 Allison N Scott AScott@policywise.com
14
15 35 Sarah A Buchan Sarah.Buchan@oahpp.ca
16
17 36 Jeffrey C Kwong jeff.kwong@utoronto.ca
18
19 37 Steven J Drews steven.drews@blood.ca
20
21 38 Kimberley A Simmonds kimberley.simmonds@gov.ab.ca
22
23 39 Lawrence W Svenson larry.svenson@gov.ab.ca
24

25 40

26
27 41

28
29 42 **Word Count:** 2,586
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **43 ABSTRACT**

4
5 **44 Introduction**

6
7 45 The appropriateness of using routinely collected laboratory data combined with administrative data for
8
9 46 estimating influenza vaccine effectiveness (VE) is still being explored. This paper outlines a protocol to
10
11 47 estimate influenza VE using linked laboratory and administrative data which could act as a companion to
12
13 48 estimates derived from other methods.

14
15
16 **49 Methods and Analysis**

17
18 50 We will use the test-negative design to estimate VE for each influenza type/subtype and season. Province-
19
20 51 wide individual-level records of positive and negative influenza tests will be linked, by unique personal health
21
22 52 numbers, to administrative databases and vaccination records to determine covariates and influenza
23
24 53 vaccination status, respectively. Covariates of interests include age, sex, immunocompromising chronic
25
26 54 conditions, and healthcare setting. Cases will be defined based on an individual's first positive influenza test
27
28 55 during the season, and potential controls will be defined based on an individual's first negative influenza test
29
30 56 during the season. One control for each case will be randomly selected based on the week the specimen was
31
32 57 collected. We will estimate vaccine effectiveness using multivariable logistic regression.

33
34
35 **58 Ethics and Dissemination**

36
37 59 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
38
39 60 under study ID Pro00075997. Results will be disseminated by public health officials in Alberta.

40
41
42 61

43
44
45 62

46
47
48 63

1
2
3 64 **Key Words**
4

5 65 Influenza
6

7 66 Vaccine effectiveness
8

9 67 Case Control
10

11 68 Test-negative
12

13 69 Administrative data
14

15 70 Population-level
16

17 71 Laboratory data
18

19 72 Vaccination database
20

21 73
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

74 **ARTICLE SUMMARY**

75 **Strengths and limitations of this study**

- 76 • This protocol describes near real time estimation of vaccine effectiveness to assist public health in
77 allocating resources and determining the appropriate policies and public messaging during the
78 influenza season.
- 79 • Vaccine effectiveness estimates use a test negative design, taking advantage of linked administrative
80 health records for the entire population.
- 81 • While many confounders are included in the vaccine effectiveness estimates, not all known
82 confounders can be measured using administrative health data.

83

For peer review only

84 INTRODUCTION

85 Influenza is a respiratory viral pathogen associated with significant morbidity and mortality globally.
86 Infections range from relatively mild presentations (e.g. cough, sore throat) to severe lower respiratory tract
87 infections (e.g. pneumonia). Severe cases may be associated with hospitalization, intensive care admission, and
88 death; young children, the elderly, and individuals with chronic conditions are at highest risk of severe
89 outcomes [1]. In Canada, rates of influenza infections are approximately 200 cases per 100,000 population,
90 with about 50% of cases occurring in patients aged ≤ 18 years [2]. The causative agents, influenza A (subtypes
91 H3N2 and H1N1pdm(09)) and influenza B (Yamagata and Victoria lineages), are under strong selective
92 pressure to mutate genetically; significant genetic changes can occur in relatively short periods of time (i.e. <1
93 year) [3].

94 Influenza prevention relies, in part, on annual vaccination campaigns that rely on vaccine strains selected
95 approximately 9 months prior to the onset of an influenza season; by the time the vaccines are administered,
96 the predominant circulating strains may have mutated to the point such that the effectiveness of the vaccine
97 has diminished or has become completely ineffective [4, 5].

98 Influenza VE is commonly estimated using the test-negative design, a variation of the case-control design
99 where cases and controls are selected from a pool of individuals who have been tested for influenza [6-10].

100 Several research groups use sentinel physician networks to recruit patients: influenza testing is performed on
101 patients who meet a case definition for influenza-like illness, and cases and controls are selected from that
102 pool [6-8]. While this has become an established method, there are some limitations to using sentinel
103 physicians. As the physicians are often volunteers, there can be bias in the geographic distribution, leading to
104 clustering of sampling in certain areas and not others. This can lead to inaccuracies as predominant
105 circulating influenza strains vary geographically [7, 11]. Immunization information is commonly self-reported,
106 potentially leading to recall and social desirability biases [12]; volunteer physicians may be more likely to have
107 strong views on influenza immunization, potentially making it more difficult for the patient to admit to not
108 being immunized. Finally, as these studies are labour-intensive for clinic staff, physician recruitment is often

1
2
3 109 low, resulting in small sample sizes and wide confidence intervals. Estimates are, therefore, typically available
4
5 110 after the peak of the influenza season, decreasing their usefulness for public health messaging and resource
6
7 111 and operational planning [6-8, 11].
8
9

10 112 Using administrative data and routinely collected clinical specimens for estimating VE is currently under
11
12 113 debate [13]. However, estimating VE in a large jurisdiction with near-real-time data on all influenza laboratory
13
14 114 testing and influenza vaccination in the population has the potential to provide more precise and timely VE
15
16 115 estimates than has previously been possible. We present a protocol to estimate influenza VE using
17
18 116 individually-linked laboratory and administrative data.
19
20

21 117
22
23

24 118 **METHODS AND ANALYSIS**

25
26

27 119 **Study Setting:**

28
29

30 120 Alberta is a province in Canada with a publicly-funded universal health care system; each of the 4.25 million
31
32 121 residents is assigned a unique personal health number (PHN) at birth or upon immigration to the province
33
34 122 [14]. The PHN is recorded each time a person accesses the healthcare system, allowing for deterministic
35
36 123 linkage across multiple administrative data sets held by the Ministry of Health.
37
38

39 124 In 2009, influenza vaccination became universally available to all Albertans aged ≥ 6 months, regardless of
40
41 125 comorbidities or other risk conditions [15]. Influenza vaccines are available at no cost to the patient at public
42
43 126 health clinics, pharmacies, physician offices, long-term care facilities, university health centers, and
44
45 127 workplaces. Annual vaccine campaigns begin in October, with approximately 60% of all influenza
46
47 128 vaccinations given by the end of the second week of the campaign. While the peak of influenza activity has
48
49 129 varied widely since 2010, the median influenza peak in Alberta is in mid-January, approximately three months
50
51 130 after vaccination campaigns begin.
52
53

54 131
55
56
57
58
59
60

132 **Laboratory methods for influenza A and B detection and influenza A subtyping**

133 All influenza testing in Alberta is performed at a single diagnostic lab, the Provincial Laboratory for Public
134 Health (ProvLab) and stored in a single laboratory information system, along with test and patient identifiers.
135 Prior to May 2017 a real-time influenza A/B reverse-transcriptase PCR (RT-PCR) was used to diagnose
136 influenza using a protocol previously described [16, 17]. After May 2017, ProvLab has been using a Luminex
137 Respiratory Pathogen Panel for the identification of influenza A (including subtype), influenza B, and other
138 respiratory viruses (e.g. coronavirus and parainfluenza) [14].

140 **Study Design:**

141 We will use the test-negative design to estimate VE. We will estimate VE for the upcoming influenza season
142 (2018/19) and past influenza seasons (2011/12 to 2016/17). The results of all respiratory virus tests
143 conducted at ProvLab will be sent to the Ministry of Health for deterministic linkage to health administrative
144 databases, in order to determine eligibility for inclusion in the analysis, influenza vaccination status, and the
145 following covariates: age, sex, socio-economic status, geographic zone of residence, history of
146 immunocompromising comorbidities, and healthcare setting (inpatient or outpatient setting) at the time of
147 specimen submission. The presence of a diagnostic code for an acute respiratory illness (ARI) at the time of
148 specimen collection will be used in a sensitivity analysis.

149 Isolates will be considered eligible for inclusion in the analysis if they met all of the following criteria: a valid
150 PHN is recorded, the isolate is not from a resident of a long-term care facility, if the seasonal threshold has
151 been reached, and the isolate was collected at least four weeks after the initiation of the public influenza
152 vaccination program [18-20].

153 It is important to ensure that the population has the chance to be exposed to influenza and there is sufficient
154 time for immunity to be developed. Residence in a long-term care facility will be determined via the Alberta
155 Continuing Care Information System (ACCIS), which contains information on admissions and discharges
156 from long-term care facilities [21]. PHN validity will be assessed using the Alberta Health Care Insurance

1
2
3 157 Plan (AHCIP) Adjusted Population Registry, which contains records of all individuals registered for
4
5 158 healthcare insurance [21, 22].
6
7

8 159 Individuals can have multiple laboratory tests over the course of their illness; therefore only the first positive
9
10 160 influenza test during the influenza season will be used, and potential control samples will be selected from
11
12 161 among those who only tested negative for influenza during that influenza season, using the first negative test.
13
14 162 Cases and controls tested <14 days after vaccination will be excluded from the analysis.
15
16

17 163 Influenza vaccination status will be determined from the Influenza Vaccination Registry. The registry
18
19 164 combines data from four databases that record influenza vaccination events (see below).
20
21

22 165 The following administrative data sets will be used in this study:
23
24

- 25 166 • Alberta Health Immunization and Adverse Reaction to Immunization system (Imm/ARI) contains
26
27 167 records of all publicly funded vaccines administered through public health, including influenza
28
29 168 vaccines administered at mass influenza vaccination clinics, public health clinics, and vaccinations
30
31 169 administered by public health nurses in long-term care facilities. Data submission is mandatory and
32
33 170 guidelines exist to support complete and accurate vaccination records with descriptions of each,
34
35 171 including notes [23, 24].
- 37 172 • The Supplemental Enhance Service Event (SESE) database captures physician claims for billing
38
39 173 purposes; International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes,
40
41 174 procedure codes, and codes indicating location of service delivery are mandatory data elements for
42
43 175 each patient encounter [22, 25, 26].
- 46 176 • Alberta Blue Cross (ABC) administers the pharmacist component of the universal vaccination
47
48 177 program. Pharmacists administering influenza vaccines through this program bill ABC for each
49
50 178 vaccine provided; they are required to submit patient information such as PHN, name, and address.
- 52 179 • The Pharmaceutical Information Network (PIN) database records privately dispensed
53
54 180 pharmacological products, including the rare instances when an influenza vaccine is purchased rather
55
56
57
58
59
60

1
2
3 181 than administered through the public program (e.g. purchased by travelers prior to the launch of the
4
5 182 public campaign). PIN captures dispensed events from >95% of pharmacists[21].
6

- 7 183 • Provincial Vaccine Registry combines influenza vaccinations given in the province and recorded in
8
9 184 four source databases (PIN, ABC, SESE and Imm/ARI).
10
11 185 • Alberta Health Care Insurance Plan Adjusted Population Registry (AHCIP) Adjusted Population
12
13 186 Registry contains demographic variables, age, sex, socio-economic status, and geographic zone of
14
15 187 residence.
16
17 188 • Morbidity and Ambulatory Care Abstracting Reporting (MACAR) system contains diagnosis codes,
18
19 189 procedure codes, the date of admission, and date of discharge for every visit to hospitals, emergency
20
21 190 rooms, and outpatient clinics.
22
23
24

25 191 Individuals will be considered inpatients if they have at least one physician claim for inpatient services on
26
27 192 the same day as specimen collection or if specimen collection occurred during an inpatient stay; all others
28
29 193 will be considered outpatients. Individuals with an immunocompromising condition will be defined as
30
31 194 those who have a diagnosis of HIV, who received an organ transplant, or received oral corticosteroids
32
33 195 (for ≥ 30 days), antineoplastic agents, or another immunocompromising drug from a community
34
35 196 pharmacist in the past 6 months. (Appendix 1 and 2) [27]. HIV diagnosis and acute respiratory illness will
36
37 197 be determined through physician claims and MACAR. Organ transplantation will be determined using
38
39 198 MACAR, and immunocompromising drug dispensations will be identified through PIN.
40
41

42 199 **Statistical Analysis**

43
44

45 200 We will use multivariable logistic regression to estimate influenza vaccine effectiveness as $(1 - \text{adjusted OR}) \times$
46
47 201 100%. We will estimate VE separately by influenza season and influenza subtype (i.e., A(H3N2),
48
49 202 A(H1N1)pdm09, and influenza B) [28]. All covariates will be considered for the adjusted model. SAS version
50
51 203 9.4 will be used for all statistical analysis (SAS Institute Inc, Cary, NC). VE estimates will be compared to
52
53 204 published estimates of VE (12-14).
54
55
56
57
58
59
60

1
2
3 205 As shedding of influenza virus continues for approximately 4-5 days after symptom onset, bias can result if
4
5 206 specimens that are collected too long after symptom onset are used [29]. Most studies use a threshold of 7
6
7 207 days [30]. To test the robustness of the findings, a sensitivity analysis will be performed; controls will be
8
9 208 restricted to those specimens positive for a different respiratory virus (i.e. coronavirus, human respiratory
10
11 209 syncytial virus) (As suggested by Sullivan et al 2016).

12
13
14 210 A potential limitation to this study is that the samples utilized here are clinical isolates taken through the
15
16 211 course of normal patient care, and are not from a standard case definition as is utilized in some other studies
17
18 212 [12]. To test the robustness of the findings, the analysis will be repeated using only cases and controls that
19
20 213 were given a diagnosis code for acute respiratory infection on the same day as specimen collection, as per the
21
22 214 SESE database or MACAR. Appendix 3 lists the ICD-9 and ICD-10 codes used to define an acute respiratory
23
24 215 infection.

26
27 216

29 217 **DISCUSSION**

30
31 218 This protocol describes the estimation of seasonal influenza VE using specimens collected for routine
32
33 219 influenza diagnostics as well as administrative data and vaccination records.

34
35
36 220 A key strength of this approach is the large sample size. This approach allows calculation of near real-time,
37
38 221 precise influenza VE estimates weeks prior to the influenza season peak, creating an early warning system for
39
40 222 public health if, as in the 2014-2015 season, the vaccine is found to have exceedingly low effectiveness. Early
41
42 223 notification of VE can assist public health in determining policies, messaging, and allocation of resources
43
44 224 (antiviral agents, staffing emergency departments) to counter a potentially more severe influenza season [31,
45
46 225 32]. The large sample size also allows for stratified analyses of VE based on product, age group, or region.

47
48
49 226 Whereas sentinel physician networks rely primarily on self-reported measures of influenza vaccination [33], a
50
51 227 significant strength of this study is the use of the near-real-time influenza vaccination registry that contains
52
53 228 individual-level, linkable data for most influenza vaccinations administered in the province. Use of this
54
55 229 registry reduces the likelihood of recall error and information biases such as social desirability bias and

1
2
3 230 reduces non-differential misclassification, which would bias the odds ratio towards the null, thus
4
5 231 underestimating VE [12].
6
7

8 232 Finally, we are certain to capture the results of all respiratory virus testing in the province, as all respiratory
9
10 233 virus testing is centralized at ProvLab and there is limited use of point-of-care testing.
11
12

13 234 There are some limitations to this methodology compared to the traditional method of VE estimation using
14
15 235 sentinel physician networks, because a standardized clinical case definition cannot be applied to determine
16
17 236 study eligibility. A sensitivity analysis restricting to healthcare encounters with a diagnosis code for acute
18
19 237 respiratory infection will be used as a proxy for a standard case definition.
20
21

22 238 While the inclusion of confounders is important for VE estimate adjustment, not all known confounders can
23
24 239 be measured using administrative data. Frailty has been demonstrated to be a potential confounder of VE
25
26 240 [34-36]. Frailty cannot be included in the multivariable model because no validated indices of frailty generated
27
28 241 from standard administrative data exist at this time. However, this may not affect the results significantly as a
29
30 242 previous study indicated that inclusion of frailty in the multivariate model increased VE estimates only slightly
31
32 243 [37].
33
34

35 244 Laboratory requisitions in Alberta do not contain onset date. Ideally this would be used to ensure that the
36
37 245 negative laboratory test results were representative of an acute infectious period and that test-negative
38
39 246 specimens were not collected after viral shedding had ceased. Sullivan et al 2016 have indicated this bias may
40
41 247 be accounted for by selecting influenza test-negative controls that were positive for another respiratory virus.
42
43 248 Requiring controls to be positive for another virus excludes individuals who are tested long after their acute
44
45 249 infectious period. However, a recent systematic review found no differences when using different groups of
46
47 250 controls [30].
48
49

50
51 251 Comparison of the VE results using administrative data to previously published studies, specifically sentinel
52
53 252 surveillance for the same seasons (2011/12 – 2018/19) will help to identify further areas of refinement.
54
55
56
57
58
59
60

1
2
3 253 This approach could successfully allow for the generation of early influenza VE estimates which could
4
5 254 facilitate tailoring of public health messaging and assist in public health operations planning for the peak of
6
7 255 the influenza season.
8

9 256

11 257 **ETHICS**

13 258 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
14
15 259 under study ID Pro00075997.
16

17 260

19 261 **LIST OF ABBREVIATIONS**

21 262 ABC – Alberta Blue Cross

23 263 ACCIS – Alberta Continuing Care Information System

25 264 AHCIP – Alberta Health Care Insurance Plan Adjusted Population Registry

27 265 CCI – Canadian Classification of Health Interventions

29 266 CCP – Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures

31 267 CIHI – Canadian Institute for Health Information

33 268 DAD – Alberta Hospital Discharge Abstract Database

35 269 ICD-9 – International Classification of Diseases, Ninth Revision

37 270 ICD-10 – International Classification of Diseases, Tenth Revision

39 271 Imm/ARI – Alberta Health Immunization and Adverse Reaction to Immunization system

41 272 MACAR – Morbidity and Ambulatory Care Abstracting Reporting

43 273 PHN – Personal Health Number

45 274 PIN – Pharmaceutical Information Network

47 275 ProvLab – Alberta Provincial Laboratory for Public Health

49 276 RT-PCR – Reverse Transcriptase Polymerase Chain Reaction

51 277 SESE – Supplemental Enhance Service Event

53 278 VE – Vaccine Effectiveness
54
55
56
57
58
59
60

1
2
3 **279 ETHICS APPROVAL AND CONSENT TO PARTICIPATE**
4

5 280 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
6
7 281 under study ID Pro00075997.
8

9 282

10
11 **283 CONSENT FOR PUBLICATION**
12

13 284 Not applicable
14
15

16 285

17
18
19 **286 AVAILABILITY OF DATA AND MATERIALS**
20

21 287 Not applicable
22
23

24 288

25
26 **289 COMPETING INTERESTS**
27

28 290 The authors declare that they have no competing interests.
29
30

31 291

32
33 **292 FUNDING**
34

35 293 Not applicable
36
37

38 294

39
40 **295 AUTHOR STATEMENT**

41 296 ANS and SJD conceived of and designed the protocol and drafted and revised the manuscript. KS and LS
42 297 planned the original approach, providing guidance on available administrative database resources. SAB and
43 298 JCK made substantial contributions to the design and critically revised the manuscript.
44
45

46 299

47
48 **300 ACKNOWLEDGEMENTS**
49

50 301 The authors would like to acknowledge the staff at Alberta Health Services and ProvLab for their assistance
51 302 in providing administrative and laboratory data sources that could be implemented in this protocol.
52

53 303
54
55
56
57
58
59
60

304

305 **REFERENCES**

- 306 1. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E,
307 Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic
308 review and meta-analysis. *BMJ*. 2013; 347:f5061.
- 309 2. Alberta Health Services. Edmonton, AB: Alberta Health Services; 2017.
- 310 3. Wong SS, Webby RJ. Traditional and new influenza vaccines. *Clin Microbiol Rev*. 2013; 26:476-492.
- 311 4. Skowronski DM, Chambers C, Sabaiduc S, De SG, Winter AL, Dickinson JA, Kraiden M, Gubbay
312 JB, Drews SJ, Martineau C, Eshaghi A, Kwindt TL, Bastien N, Li Y. A Perfect Storm: Impact of
313 Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-
314 2015 Season. *Clin Infect Dis* 2016; 63:21-32.
- 315 5. World Health Organization. Influenza Update 309. World Health Organization; 2017.
- 316 6. Skowronski DM, De SG, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, Rosella LC, Dickinson
317 JA, Gilca R, Sethi P, Ouhoummane N, Willison DJ, Rouleau I, Petric M, Fonseca K, Drews SJ,
318 Rebbapragada A, Charest H, Hamelin ME, Boivin G, Gardy JL, Li Y, Kwindt TL, Patrick DM,
319 Brunham RC. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1
320 illness during Spring-Summer 2009: four observational studies from Canada. *PLoS Med*. 2010;
321 7:e1000258.
- 322 7. Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De SG, Gubbay JB, Drews SJ,
323 Martineau C, Eshaghi A, Kraiden M, Bastien N, Li Y. Interim estimates of 2015/16 vaccine
324 effectiveness against influenza A(H1N1)pdm09, Canada, February 2016. *Euro Surveill*. 2016;
325 21:30168.
- 326 8. Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha R, Turner R, Rosella LC,
327 Crowcroft NS. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among
328 elderly adults during the 2010-2011 season. *Clin Infect Dis*. 2013; 57:820-827.
- 329 9. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B. Field
330 evaluation of vaccine efficacy. *Bull World Health Organ*. 1985; 63:1055-1068.
- 331 10. Public Health Agency of Canada. Effectiveness of vaccine against medical consultation due to
332 laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia,
333 2004-2005. *Can Commun Dis Rep*. 2005; 31:181-191.
- 334 11. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De SG, Drews SJ, Jassem A,
335 Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Kraiden M. Interim estimates of 2016/17
336 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. *Euro Surveill*. 2017; 22.
- 337 12. World Health Organization. Evaluation of influenza vaccine effectiveness: a guide to the design and
338 interpretation of observational studies. World Health Organization; 2017.

- 1
2
3 339 13. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ.
4 340 Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-
5 341 negative design studies. *Lancet Infect Dis.* 2016; 16:942-951.
6
7 342 14. Fathima S, Simmonds K, Invik J, Scott AN, Drews S. Use of laboratory and administrative data to
8 343 understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and
9 344 pneumonia in Alberta, Canada. *BMC Infect Dis.* 2016; 16:402.
10
11 345 15. Alberta Health: History of immunization in Alberta. Edmonton, AB: Government of Alberta; 2017.
12
13 346 16. Pabbaraju K, Wong S, Wong AA, Appleyard GD, Chui L, Pang XL, Yanow SK, Fonseca K, Lee BE,
14 347 Fox JD, Preiksaitis JK. Design and validation of real-time reverse transcription-PCR assays for
15 348 detection of pandemic (H1N1) 2009 virus. *J Clin Microbiol.* 2009; 47:3454-3460.
16
17 349 17. Chaudhry A, Bastien N, Li Y, Scott A, Pabbaraju K, Stewart D, Wong S, Drews SJ. Influenza Other
18 350 Respir Viruses. 2016; 10:532-535.
19
20 351 18. World Health Organization. Global epidemiological surveillance standards for influenza. World
21 352 Health Organization; 2013.
22
23 353 19. World Health Organization. A manual for estimating disease burden associated with seasonal
24 354 influenza.; World Health Organization; 2015.
25
26 355 20. Alberta Health. Seasonal Influenza in Alberta 2016/2017 Summary Report. Alberta Health,
27 356 Edmonton, AB: Government of Alberta; 2017.
28
29 357 21. Government of Alberta. Overview of administrative health datasets. Edmonton, AB: Government of
30 358 Alberta; 2017.
31
32 359 22. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles
33 360 in Alberta. *Epidemiol Infect.* 2007; 135:908-913.
34
35 361 23. Government of Alberta: Immunization data submission and response guidelines. Version 5.9.
36 362 Edmonton, AB: Government of Alberta; 2017.
37
38 363 24. MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of
39 364 measles-mumps-rubella-varicella vaccine: a population-based cohort study. *CMAJ.* 2014; 186:824-
40 365 829.
41
42 366 25. Alberta Health: Alberta Health Claims Assessment. 2017.
43 367 <https://open.alberta.ca/publications/alberta-health-diagnostic-codes>. Accessed Feb 23, 2018.
44
45 368 26. Lix LM, Walker R, Quan H, Nesdole R, Yang J, Chen G, CHEP-ORTF. Hypertension Outcomes
46 369 and Surveillance Team. Hypertension Outcomes and Surveillance Team: Features of physician
47 370 services databases in Canada. *Chronic Diseases and Injuries in Canada.* 2012; 32.
48
49 371 27. Schwartz KL, Jembere N, Campitelli MA, Buchan SA, Chung H, Kwong JC. Using physician billing
50 372 claims from the Ontario Health Insurance Plan to determine individual influenza vaccination status:
51 373 an updated validation study. *CMAJ Open.* 2016; 4:E463-E470.
52
53 374 28. Sullivan SG, Cowling BJ. "Crude Vaccine Effectiveness" Is a Misleading Term in Test-negative
54 375 Studies of Influenza Vaccine Effectiveness. *Epidemiology.* 2015; 26:e60.
55
56
57
58
59
60

- 1
2
3 376 29. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study
4 377 Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol.* 2016; 184:345-353.
5
6 378 30. Feng S, Cowling BJ, Kelly H, Sullivan SG. Estimating Influenza Vaccine Effectiveness With the
7 379 Test-Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis.
8 380 *Am J Epidemiol.* 2018; 187:389-397.
9
10 381 31. Orton L, Lloyd-Williams F, Taylor-Robinson D, O'Flaherty M, Capewell S. The use of research
11 382 evidence in public health decision making processes: systematic review. *PLoS One.* 2011; 6:e21704.
12
13 383 32. Savel TG, Foldy S. The role of public health informatics in enhancing public health surveillance.
14 384 *MMWR Suppl.* 2012; 61:20-24.
15
16 385 33. Skowronski DM, Janjua NZ, De SG, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL,
17 386 Gubbay JB, Kraiden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van CP, Li Y.
18 387 Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2
19 388 vaccine strain not antigenic drift in circulating viruses. *PLoS One.* 2014; 9:e92153.
20
21 389 34. Nelson JC, Jackson ML, Weiss NS, Jackson LA. New strategies are needed to improve the accuracy
22 390 of influenza vaccine effectiveness estimates among seniors. *J Clin Epidemiol.* 2009; 62:687-694.
23
24 391 35. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of
25 392 influenza vaccine effectiveness in seniors. *Int J Epidemiol.* 2006; 35:337-344.
26
27 393 36. Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM, Heckbert SR, Larson EB, Weiss
28 394 NS. Functional status is a confounder of the association of influenza vaccine and risk of all cause
29 395 mortality in seniors. *Int J Epidemiol.* 2006; 35:345-352.
30
31 396 37. Talbot HK, Nian H, Chen Q, Zhu Y, Edwards KM, Griffin MR. Evaluating the case-positive,
32 397 control test-negative study design for influenza vaccine effectiveness for the frailty bias. *Vaccine.*
33 398 2016; 34:1806-1809.
34 399
35 400
36
37
38 401

1
2
3 **402 Appendix 1. List of CCP, CCI, and CMG codes utilized to define individuals who have had an organ**
4
5 **403 transplant**
6
7

8 **CCP Code Description**

9 495	Heart Transplantation
10 455	Lung Transplant
11 456	Combined Heart-Lung Transplantation
12 624	Liver Transplant
13 675	Transplant of Kidney
14 648	Transplant of Pancreas

16
17 **CCI Code Description**

18 1HY85	Transplant, Heart With Lung(S)
19 1HZ85	Transplant, Heart Nec
20 1GT85	Transplant, Lung Nec
21 1GR85	Transplant, Lobe of Lung
22 1OA85	Transplant, Liver
23 1PC85	Transplant, Kidney
24 1OJ85	Transplant, Pancreas
25 1OK85	Transplant, Pancreas With Duodenum
26 1NK85	Transplant, Small Intestine
27 1NP85	Transplant, Small And Large Intestine

29
30 **CMG 1992 To 2005**

31 175	Heart or Lung Transplant
32 253	Major Intestinal And Rectal Procedures
33 310	Liver Transplant
34 311	Major Pancreatic Procedures
35 500	Kidney Transplant

37
38 **CMG 2007 To 2016**

39 110	Lung Transplant
40 160	Heart Transplant
41 220	Major Upper Gastrointestinal Reconstruction/Excision
42 270	Liver/Pancreas/Duodenum Transplant
43 450	Kidney Transplant

44 404

46 405

49 406

407 Appendix 2. List of drug names and DINs utilized to define immunocompromising conditions

DIN	Drug Name	Route of Administration	Strength
00616192	ETOPOSIDE	CAP	50MG
00523410	ETOPOSIDE	IV SOL	20MG/ML
02080036	ETOPOSIDE	IV SOL	20MG/ML
02241182	ETOPOSIDE	IV SOL	20MG/ML
02231622	IRINOTECAN HCL	IV SOL	20MG/ML
02258218	IRINOTECAN HCL	IV SOL	20MG/ML
00015431	VINBLASTINE SULFATE	IV PWS	1MG/ML
00611182	VINCRISTINE SULFATE	IV SOL	1MG/ML
02143305	VINCRISTINE SULFATE	IV SOL	1MG/ML
00004618	BUSULFAN	TAB	2MG
00297763	CARMUSTINE	IV PWS	100MG
09851399	CARMUSTINE	TOP SOL	NOT AVLE
00004626	CHLORAMBUCIL	TAB	2MG
00344915	CYCLOPHOSPHAMIDE	INJ PWS	2GM
00013544	CYCLOPHOSPHAMIDE	IV PWS	200MG
00013552	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241797	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241799	CYCLOPHOSPHAMIDE	IV PWS	1000MG
00013749	CYCLOPHOSPHAMIDE	TAB	50MG
00262676	CYCLOPHOSPHAMIDE	TAB	25MG
00344877	CYCLOPHOSPHAMIDE	TAB	25MG
00344885	CYCLOPHOSPHAMIDE	TAB	50MG
02241795	CYCLOPHOSPHAMIDE	TAB	25MG
02241796	CYCLOPHOSPHAMIDE	TAB	50MG
02063794	ESTRAMUSTINE DISODIUM PHOSPHATE	CAP	140MG
00780278	ESTRAMUSTINE PHOSPHATE	CAP	140MG
00360414	LOMUSTINE	CAP	100MG
00360422	LOMUSTINE	CAP	40MG
00360430	LOMUSTINE	CAP	10MG
00016063	MECHLORETHAMINE	IV PWS	10MG
00004715	MELPHALAN	TAB	2MG
02312794	TEMOZOLOMIDE	CAP	140MG
02312816	TEMOZOLOMIDE	CAP	180MG
02395274	TEMOZOLOMIDE	CAP	20MG
02395282	TEMOZOLOMIDE	CAP	100MG
02395290	TEMOZOLOMIDE	CAP	140MG
02395312	TEMOZOLOMIDE	CAP	250MG
02443473	TEMOZOLOMIDE	CAP	5MG
02443481	TEMOZOLOMIDE	CAP	20MG

DIN	Drug Name	Route of Administration	Strength
02443511	TEMOZOLOMIDE	CAP	100MG
02443538	TEMOZOLOMIDE	CAP	140MG
02443554	TEMOZOLOMIDE	CAP	250MG
02241093	TEMOZOLOMIDE	CAP	5MG
02241094	TEMOZOLOMIDE	CAP	20MG
02241095	TEMOZOLOMIDE	CAP	100MG
02241096	TEMOZOLOMIDE	CAP	250MG
02441160	TEMOZOLOMIDE	CAPSULE	5MG
00237035	THIOTEPA	INJ PWS	15MG/ML
02421917	CAPECITABINE	FC TAB	150MG
02421925	CAPECITABINE	FC TAB	500MG
02426757	CAPECITABINE	FC TAB	150MG
02426765	CAPECITABINE	FC TAB	500MG
02400022	CAPECITABINE	TAB	150MG
02400030	CAPECITABINE	TAB	500MG
02238453	CAPECITABINE	TAB	150MG
02238454	CAPECITABINE	TAB	500MG
02022117	CLADRIBINE	IV SOL	1MG
00194727	CYTARABINE	INJ PWS	500MG
00386715	CYTARABINE	INJ PWS	100MG
02167867	CYTARABINE	INJ PWS	100MG
00646296	CYTARABINE	IV PWS	1GM
00646318	CYTARABINE	IV PWS	2GM
02246226	FLUDARABINE PHOSPHATE	TAB	10MG
00012882	FLUOROURACIL	IV SOL	
00330582	FLUOROURACIL	TOP CRM	5%
00465283	HYDROXYUREA	CAP	500MG
02242920	HYDROXYUREA	CAP	500MG
02247937	HYDROXYUREA	CAP	500MG
00004723	MERCAPTOPYRINE	TAB	50MG
02415275	MERCAPTOPYRINE	TABLET	50MG
09857520	METHOTREXATE	INJ SOL	50MG/2ML
02182777	METHOTREXATE	INJ SOL	25MG/ML
02182955	METHOTREXATE	INJ SOL	25MG/ML
00014915	METHOTREXATE	TAB	2.5MG
02170698	METHOTREXATE	TAB	2.5MG
02182750	METHOTREXATE	TAB	10MG
02182963	METHOTREXATE	TAB	2.5MG
02244798	METHOTREXATE	TAB	2.5MG
02398427	METHOTREXATE	VIAL	25MG/ML
00321397	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
00321400	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
02170663	METHOTREXATE DISODIUM	INJ SOL	50MG/2ML
02170671	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
02182947	METHOTREXATE SODIUM	INJ SOL	10MG/ML
00614335	METHOTREXATE SODIUM	IV SOL	10MG/ML
00874132	METHOTREXATE SODIUM	TAB	2.5MG
02171767	METHOTREXATE SODIUM	TAB	2.5MG
00282081	THIOGUANINE	TAB	40MG
02384256	CRIZOTINIB	CAP	200MG
02384264	CRIZOTINIB	CAP	250MG
02409607	DABRAFENIB	CAP	50MG
02409615	DABRAFENIB	CAP	75MG
02320193	DASATINIB	TAB	100MG
02293129	DASATINIB	TAB	20MG
02293137	DASATINIB	TAB	50MG
02293145	DASATINIB	TAB	70MG
02269007	ERLOTINIB HCL	TAB	25MG
02269015	ERLOTINIB HCL	TAB	100MG
02269023	ERLOTINIB HCL	TAB	150MG
02377705	ERLOTINIB HCL	TABLET	100MG
02377713	ERLOTINIB HCL	TABLET	150MG
02434407	IBRUTINIB	CAP	140MG
09857447	IMATINIB MESYLATE	TAB	100MG
02388006	RUXOLITINIB	TAB	5MG
02388014	RUXOLITINIB	TAB	15MG
02388022	RUXOLITINIB	TAB	20MG
02409658	TRAMETINIB RECOMBINANT	TAB	2MG
01926438	ASPARAGINASE	INJ PWS	10MU
02389649	AXITINIB	TAB	5MG
02389630	AXITINIB	TAB FC	1MG
02262452	BORTEZOMIB	IV PWS	3.5MG
00521183	DACARBAZINE	IV PWS	200MG/VIAL
02154854	DACARBAZINE	IV PWS	200MG
02248676	GEFITINIB	TAB	250MG
02244725	IMATINIB MESYLATE	CAP	100MG
02399806	IMATINIB MESYLATE	FC TAB	100MG
02355337	IMATINIB MESYLATE	TAB	100MG
02355345	IMATINIB MESYLATE	TAB	400MG
02397285	IMATINIB MESYLATE	TAB	100MG
02397293	IMATINIB MESYLATE	TAB	400MG
02399814	IMATINIB MESYLATE	TAB	400MG
02431114	IMATINIB MESYLATE	TAB	100MG
02431122	IMATINIB MESYLATE	TAB	400MG

DIN	Drug Name	Route of Administration	Strength
09857448	IMATINIB MESYLATE	TAB	400MG
02253275	IMATINIB MESYLATE	TAB	100MG
02253283	IMATINIB MESYLATE	TAB	400MG
02326442	LAPATINIB DITOSYLATE	TAB	250MG
02315874	NILOTINIB	CAP	200MG
02368250	NILOTINIB	CAP	150MG
02352303	PAZOPANIB HCL	TAB	200MG
00012750	PROCARBAZINE HCL	CAP	50MG
02403390	REGORAFENIB	TAB	40MG
02284227	SORAFENIB TOSYLATE	TAB	200MG
02280795	SUNITINIB MALATE	CAP	12.5MG
02280809	SUNITINIB MALATE	CAP	25MG
02280817	SUNITINIB MALATE	CAP	50MG
02258595	ADALIMUMAB	INJ-SC SOL	40MG
09854785	ADALIMUMAB	INJ-SC SOL	40MG
09857294	ADALIMUMAB	INJ-SC SOL	40MG
09857326	ADALIMUMAB	INJ-SC SOL	40MG
09857327	ADALIMUMAB	INJ-SC SOL	40MG
02130181	ALDESLEUKIN	IV PWS	1.3MG
02331675	CERTOLIZUMAB PEGOL	INJ-SC SOL	200MG/ML
09857394	ETANERCEPT RECOMBINANT	INJ SOL	50MG/ML
02242903	ETANERCEPT RECOMBINANT	INJ-SC PWS	25MG
02274728	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
09857322	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
02233014	GLATIRAMER	INJ-SC PWS	20MG
02245619	GLATIRAMER	INJ-SC SOL	20MG/ML
02324776	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02324784	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02244016	INFLIXIMAB	IV PWS	100MG
09852956	INFLIXIMAB	IV PWS	100MG
02419475	INFLIXIMAB	PWD VIAL	100MG
02239832	INTERFERON	INJ-SC SOL	0.03MG/ML
09852751	INTERFERON	OPH SOL	1MU/ML
02223384	INTERFERON ALFA 2B	INJ PWS	3MMU
02223392	INTERFERON ALFA 2B	INJ PWS	5MMU
02223406	INTERFERON ALFA 2B	INJ PWS	10MMU
02231651	INTERFERON ALFA 2B	INJ PWS	18MMU
00889067	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02223414	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02238674	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
02238675	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
09853995	INTERFERON ALFA 2B	INJ SOL	10MU/VIAL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
09854045	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
09854053	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
00705896	INTERFERON ALFA 2B	INJ-SC SOL	3MMU
00705918	INTERFERON ALFA 2B	INJ-SC SOL	5MMU
00705926	INTERFERON ALFA 2B	INJ-SC SOL	10MMU
02240693	INTERFERON ALFA 2B	INJ-SC SOL	18MMU/1.2ML
02240694	INTERFERON ALFA 2B	INJ-SC SOL	30MMU/1.2ML
02240695	INTERFERON ALFA 2B	INJ-SC SOL	60MMU/1.2ML
01911988	INTERFERON ALFA-2A	INJ PWS	3000MU/ML
01911996	INTERFERON ALFA-2A	INJ PWS	9000MU/ML
01912003	INTERFERON ALFA-2A	INJ PWS	6000MU/ML
00812471	INTERFERON ALFA-2A	INJ PWS	6000MU/ML
00812498	INTERFERON ALFA-2A	INJ SOL	6000MU/ML
00812501	INTERFERON ALFA-2A	INJ SOL	3000MU/ML
02217015	INTERFERON ALFA-2A	INJ SOL	3000MU/ML
02217031	INTERFERON ALFA-2A	INJ SOL	6000MU/ML
02217058	INTERFERON ALFA-2A	INJ SOL	9000MU/ML
02217066	INTERFERON ALFA-2A	INJ SOL	18000MU/ML
02019914	INTERFERON ALFA-2A	INJ SOL	9000MU/ML
01959069	INTERFERON ALPHA-N1	INJ SOL	10MU
01959077	INTERFERON ALPHA-N1	INJ SOL	3MU
00709042	INTERFERON ALPHA-N1	INJ SOL	3MU
00709050	INTERFERON ALPHA-N1	INJ SOL	10MU
02169649	INTERFERON BETA	INJ-SC PWS	0.3MG
02237317	INTERFERON BETA 1A	INJ PWS	11MCG
02237318	INTERFERON BETA 1A	INJ PWS	44MCG
02237770	INTERFERON BETA 1A	INJ-IM PWS	30MCG/1.1ML
02269201	INTERFERON BETA 1A	INJ-IM SOL	30MCG/0.5ML
02318253	INTERFERON BETA 1A	INJ-SC SOL	66MCG/1.5ML
02318261	INTERFERON BETA 1A	INJ-SC SOL	132MCG/1.5ML
02237319	INTERFERON BETA 1A	INJ-SC SOL	22MCG/0.5ML
02237320	INTERFERON BETA 1A	INJ-SC SOL	44MCG/0.5ML
09857395	INTERFERON BETA-1A	PREF AUTOINJ PEN	30MCG/0.5ML
02337819	INTERFERON BETA-1B	RECOMBINANT	INJ-SC PWS
00846368	RECOMBINANT	INJ-SC PWS	0.3MG
00846368	LEVAMISOLE HCL	TAB	50MG
02234217	LEVAMISOLE HCL	TAB	50MG
09857505	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
09857505	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248077	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
02248077	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248078	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
02248078	RECOMBINANT	INJ-SC SOL	180MCG/ML

DIN	Drug Name	Route of Administration	Strength
00258482	BLEOMYCIN SULFATE	INJ PWS	15U
00163899	DAUNORUBICIN HCL	INJ PD	20MG
01926683	DAUNORUBICIN HCL	IV PWS	20MG
00353078	DOXORUBICIN HCL	IV PWS	50MG
00357391	DOXORUBICIN HCL	IV PWS	10MG
00640050	EPIRUBICIN HCL	INJ PWS	10MG
00640069	EPIRUBICIN HCL	IV PWS	50MG
00381799	MITOMYCIN	IV PWS	5MG
00463221	MITOTANE	TAB	500MG
02415992	AFLIBERCEPT	VIAL	40MG/ML
02273993	ALEMTUZUMAB	IV SOL	10MG/ML
02290960	ALEMTUZUMAB	IV SOL	30MG/ML
02270994	BEVACIZUMAB	IV SOL	25MG/ML
09857407	RITUXIMAB	IV SOL	10MG/ML
02241927	RITUXIMAB	IV SOL	10MG/ML

408

409

410 **Appendix 4. ICD-9 codes and ICD-10 codes utilized to define acute respiratory illness in physician,**
 411 **ER and hospital encounters.**

Description	ICD-9 Code	ICD-10 Code
Viral infection, unspecified site	079	B34
Viral agents as the cause of diseases classified to other chapters	--	B97 (but not B973 or B977)
Acute nasopharyngitis (common cold)	460	J00
Acute sinusitis	461	J01
Acute pharyngitis	462	J02
Acute tonsillitis	463	J03
Acute laryngitis, tracheitis, epiglottitis, croup	464	J04, J05
Acute upper respiratory infections of multiple or unspecified sites	465	J06
Influenza due to identified novel influenza A virus	488	J09
Influenza	487	J10, J11
Pneumonia, organism unspecified	486	--
Viral pneumonia	480	J12
Bacterial pneumonia	481, 482	J13, J14, J15
Pneumonia due to other specified organism	483	J16
Pneumonia in infectious diseases classified elsewhere	484	J17
Bronchopneumonia, organism unspecified	485	J18
Acute bronchitis and bronchiolitis	466	J20, J21
Unspecified diseases respiratory system	519	J22, J39.8, J39.9
Bronchitis, not specified as acute or chronic	490	J40
Acute respiratory distress syndrome	518.82	J80
Pulmonary edema	518.4	J81
Pleural effusion	510.9, 511.0, 511.1, 511.89	J86.9, J90, R09.1
Respiratory failure	518.81	J96.0, J96.9
Atelectasis	--	J98.10
Pulmonary collapse	518.0	J98.19
Other respiratory disorders	786.00, 786.09	J98.0, J98.4, J98.8, J98.9
Hemoptysis	786.30	R04.2
Cough	786.2	R05
Shortness of breath (dyspnea)	786.02, 786.05, 786.09	R06.0
Stridor	786.1	R06.1
Wheezing	786.07	R06.2
Tachypnea	786.06	R06.4
Chest pain on breathing	786.52	R07.1
Hypoxemia	799.02	R09.0
Respiratory arrest	799.1	R09.2
Abnormal sputum	786.4	R09.3
Nasal congestion	478.19	R09.81
Abnormal chest sounds	786.7	R09.89

	Description	ICD-9 Code	ICD-10 Code
	Fever	780.60	R50
	Chills (without fever)	780.64	R68.0
	Sepsis, shock	669.11, 669.12, 669.14, 785.50, 785.52, 995.91, 995.92	A41.9, R57.9

412

413

For peer review only

BMJ Open

Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029708.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Apr-2019
Complete List of Authors:	Scott, Allison; Government of Alberta, Ministry of Health; PolicyWise for Children & Families Buchan, Sarah; Institute for Clinical Evaluative Sciences; Public Health Ontario Kwong, Jeff; Institute for Clinical Evaluative Sciences Drews, Steven; Alberta Provincial Laboratory for Public Health; University of Alberta, Division of Preventive Medicine Simmonds, Kimberley; Alberta Ministry of Health, Epidemiology and Surveillance Svenson, Lawrence; Government of Alberta, Ministry of Health; University of Calgary Cumming School of Medicine, Department of Community Health Sciences
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Public health, Epidemiology
Keywords:	Influenza, Vaccine effectiveness, Case Control, Test-negative, Administrative data, Population level

SCHOLARONE™
Manuscripts

1
2
3 1 **TITLE**

4
5 2 **Using population-wide administrative and laboratory data to estimate type- and subtype-specific**
6 3 **influenza vaccine effectiveness: a surveillance protocol**

7
8 4 Allison N Scott^{1,2,3}

9
10 5 Sarah A Buchan^{4,5,6}

11
12 6 Jeffrey C Kwong^{4,5,6,7,8}

13
14 7 Steven J Drews^{9,10}

15
16 8 Kimberley A Simmonds^{1,11}

17
18 9 Lawrence W Svenson^{1,11, 12, 13}

19
20
21 10

22 11 **Affiliations**

23
24 12 ¹Ministry of Health, Government of Alberta, Edmonton, AB, Canada

25
26 13 ²PolicyWise for Children & Families, Edmonton, AB, Canada

27
28 14 ³Department of Public Health, Concordia University of Edmonton, AB, Canada

29
30 15 ⁴ICES, Toronto, ON, Canada

31
32 16 ⁵Public Health Ontario, Toronto, ON, Canada

33
34 17 ⁶Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

35
36 18 ⁷Department of Family & Community Medicine, University of Toronto, Toronto, ON, Canada

37
38 19 ⁸University Health Network, Toronto, ON, Canada

39
40 20 ⁹The Alberta Provincial Laboratory for Public Health, Edmonton, AB, Canada

41
42 21 ¹⁰Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada

43
44 22 ¹¹ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary,
45 23 AB, Canada

46
47 24 ¹² School of Public Health, University of Alberta, Edmonton, AB, Canada

48
49 25 ¹³ Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada

50
51
52 26

53
54 27 **Corresponding Author:**

55
56 28 Allison N. Scott, Ph.D.

1
2
3 29 PolicyWise for Children & Families
4
5 30 1000, 9925-109 Street NW
6
7 31 Edmonton, Alberta, Canada T5K 2J8
8

9 32

10
11 33 **Email Addresses**

12
13 34 Allison N Scott AScott@policywise.com
14
15 35 Sarah A Buchan Sarah.Buchan@oahpp.ca
16
17 36 Jeffrey C Kwong jeff.kwong@utoronto.ca
18
19 37 Steven J Drews steven.drews@blood.ca
20
21 38 Kimberley A Simmonds kimberley.simmonds@gov.ab.ca
22
23 39 Lawrence W Svenson larry.svenson@gov.ab.ca
24

25 40

26
27 41

28
29 42 **Word Count:** 2,502
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **43 ABSTRACT**

4
5 **44 Introduction**

6
7 45 The appropriateness of using routinely collected laboratory data combined with administrative data for
8
9 46 estimating influenza vaccine effectiveness (VE) is still being explored. This paper outlines a protocol to
10
11 47 estimate influenza VE using linked laboratory and administrative data which could act as a companion to
12
13 48 estimates derived from other methods.

14
15
16 **49 Methods and Analysis**

17
18 50 We will use the test-negative design to estimate VE for each influenza type/subtype and season. Province-
19
20 51 wide individual-level records of positive and negative influenza tests at the Provincial Laboratory for Public
21
22 52 Health in Alberta will be linked, by unique personal health numbers, to administrative databases and
23
24 53 vaccination records held at the Ministry of Health in Alberta to determine covariates and influenza
25
26 54 vaccination status, respectively. Covariates of interests include age, sex, immunocompromising chronic
27
28 55 conditions, and healthcare setting. Cases will be defined based on an individual's first positive influenza test
29
30 56 during the season, and potential controls will be defined based on an individual's first negative influenza test
31
32 57 during the season. One control for each case will be randomly selected based on the week the specimen was
33
34 58 collected. We will estimate vaccine effectiveness using multivariable logistic regression.

35
36
37 **59 Ethics and Dissemination**

38
39 60 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
40
41 61 under study ID Pro00075997. Results will be disseminated by public health officials in Alberta.

42
43
44 62

45
46
47 63

48
49
50 64

1
2
3 65 **Key Words**
4

5 66 Influenza
6

7 67 Vaccine effectiveness
8

9 68 Case Control
10

11 69 Test-negative
12

13 70 Administrative data
14

15 71 Population-level
16

17 72 Laboratory data
18

19 73 Vaccination database
20

21 74
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 75 **ARTICLE SUMMARY**
4

5 76 **Strengths and limitations of this study**
6

- 7 77 • A strength of this protocol is that it provides near real time estimation of vaccine effectiveness to
8 78 assist public health in allocating resources and determining the appropriate policies and public
9 79 messaging during the influenza season.
10 79
11 80 • Vaccine effectiveness estimates use a test negative design, taking advantage of linked administrative
12 81 health records for the entire population.
13 82
14 82 • While many confounders are included in the vaccine effectiveness estimates, not all known
15 83 confounders can be measured using administrative health data.
16
17 84

85 INTRODUCTION

86 Influenza is a respiratory viral disease associated with significant morbidity and mortality globally. Infections
87 range from relatively mild presentations (e.g. cough, sore throat) to severe lower respiratory tract infections
88 (e.g. pneumonia). Severe cases may be associated with hospitalization, intensive care admission, and death;
89 young children, the elderly, and individuals with chronic conditions are at highest risk of severe outcomes[1].
90 In Canada, rates of laboratory-confirmed influenza infections are, on average, approximately 200 cases per
91 100,000 population, with approximately 50% of cases occurring in patients aged ≤ 18 years [2]. The causative
92 agents, influenza A (subtypes H3N2 and H1N1pdm(09)) and influenza B (Yamagata and Victoria lineages),
93 are under strong selective pressure to mutate genetically; significant genetic changes can occur in relatively
94 short periods of time (i.e. < 1 year) [3].

95 Influenza prevention relies, in part, on annual vaccination campaigns. Selection of viral strains for inclusion
96 in the vaccine occurs approximately 9 months prior to the onset of the influenza season; by the time the
97 vaccines are administered, the predominant circulating strains may have mutated to the point such that the
98 effectiveness of the vaccine has diminished or has become completely ineffective [4,5].

99 Influenza VE is commonly estimated using the test-negative design, a variation of the case-control design
100 where cases and controls are selected from a pool of individuals who have been tested for influenza [6–10].
101 Several research groups use sentinel physician networks to recruit patients: influenza testing is performed on
102 patients who meet a case definition for influenza-like illness, and cases and controls are selected from that
103 pool [6–8]. While this has become an established method, there are some limitations to using sentinel
104 physicians. As the physicians are often volunteers, there can be bias in the geographic distribution, leading to
105 clustering of sampling in certain areas and not others. This can lead to inaccuracies as predominant
106 circulating influenza strains vary geographically [7,11]. Immunization information is commonly self-reported,
107 potentially leading to recall and social desirability biases [12]; volunteer physicians may be more likely to have
108 strong views on influenza immunization, potentially making it more difficult for the patient to admit to not
109 being immunized. Finally, as these studies are labour-intensive for clinic staff, physician recruitment is often

1
2
3 110 low, resulting in small sample sizes and wide confidence intervals. Estimates are, therefore, typically available
4
5 111 after the peak of the influenza season, decreasing their usefulness for public health messaging and resource
6
7 112 and operational planning [6–8,11].
8
9

10 113 Using administrative data and routinely collected clinical specimens for estimating VE is currently under
11
12 114 debate [13]. VE estimates generated using linked health administrative and laboratory data in the province
13
14 115 Ontario have been shown to be comparable to previously published estimates [manuscript under review].
15
16 116 There has been one published estimate of Alberta-specific vaccine effectiveness using a sentinel surveillance
17
18 117 system[11]; however, because of the small sample size the confidence interval was large, ranging from 8% to
19
20 118 72%. Estimating VE in a large jurisdiction with near-real-time data on all influenza laboratory testing and
21
22 119 influenza vaccination in the population has the potential to provide more precise and timely VE estimates
23
24 120 than has previously been possible. We present a protocol to estimate influenza VE using individually-linked
25
26 121 laboratory and administrative data.
27
28

29 122

30 31 32 123 **METHODS AND ANALYSIS**

33 34 35 124 **Study Setting:**

36
37
38 125 Alberta is a province in Canada with a publicly-funded universal health care system; each of the 4.25 million
39
40 126 residents is assigned a unique personal health number (PHN) at birth or upon immigration to the province
41
42 127 [14]. The PHN is recorded each time a person accesses the healthcare system, allowing for deterministic
43
44 128 linkage across multiple administrative data sets held by the Ministry of Health.

45
46
47 129 In 2009, influenza vaccination became universally available to all Albertans aged ≥ 6 months, regardless of
48
49 130 comorbidities or other risk conditions [15]. Influenza vaccines are available at no cost to the patient at public
50
51 131 health clinics, pharmacies, physician offices, long-term care facilities, university health centers, and
52
53 132 workplaces. Annual vaccine campaigns begin in October, with approximately 60% of all influenza
54
55 133 vaccinations given by the end of the second week of the campaign. While the peak of influenza activity has
56
57

1
2
3 134 varied widely since 2010, the median influenza peak in Alberta is in mid-January, approximately three months
4
5 135 after vaccination campaigns begin.
6
7

8 136

11 137 **Laboratory methods for influenza A and B detection and influenza A subtyping**

12
13 138 All influenza testing in Alberta is performed at a single diagnostic lab, the Provincial Laboratory for Public
14
15 139 Health (ProvLab) and stored in a single laboratory information system, along with test and patient identifiers.
16
17 140 Clinical specimens (e.g. nasopharyngeal swabs, nasopharyngeal aspirates, bronchoalveolar lavages) are
18
19 141 processed at ProvLab using previously published protocols. Nucleic acid extraction utilizes the easyMAG
20
21 142 extractor and reagents (bioMerieux, St. Laurent, Quebec, Canada)[16]. Nucleic acid from clinical specimens are
22
23 143 then tested using a series of respiratory detection assays as described below. Prior to May 2017, a real-time
24
25 144 influenza A/B reverse-transcriptase PCR (RT-PCR) was used to diagnose influenza using a protocol
26
27 145 previously described [17,18]. After May 2017, ProvLab has been using a Luminex Respiratory Pathogen Panel
28
29 146 for the identification of influenza A (including subtype), influenza B, and other respiratory viruses (e.g.
30
31 147 coronavirus and parainfluenza) [14]. Results of the laboratory testing were imported into specific laboratory
32
33 148 information systems depending on the testing time period.
34
35

36 149

38 150 **Study Design:**

39
40
41 151 We will use the test-negative design to estimate VE. We will estimate VE for the 2011/12 – 2018/19
42
43 152 influenza seasons. The results of all respiratory virus tests conducted at ProvLab will be sent to the Ministry
44
45 153 of Health for deterministic linkage to health administrative databases, in order to determine eligibility for
46
47 154 inclusion in the analysis, influenza vaccination status, and the following covariates: age, sex, socio-economic
48
49 155 status, geographic zone of residence, history of immunocompromising comorbidities, healthcare setting
50
51 156 (inpatient or outpatient setting), and month at the time of specimen submission. The presence of a diagnostic
52
53 157 code for an acute respiratory illness (ARI) at the time of specimen collection will be used in a sensitivity
54
55 158 analysis.
56
57
58
59
60

1
2
3 159 Isolates will be considered eligible for inclusion in the analysis if they met all of the following criteria: a valid
4
5 160 PHN is recorded, the isolate is not from a resident of a long-term care facility, the isolate was collected at
6
7 161 least four weeks after the initiation of the public influenza vaccination program, and the isolate was collected
8
9 162 during the influenza season, as determined using the method recommended by the WHO [19–21].

11
12 163 It is important to ensure that the population has the chance to be exposed to influenza and there is sufficient
13
14 164 time for immunity to the vaccine to be developed. Residence in a long-term care facility will be determined
15
16 165 via the Alberta Continuing Care Information System (ACCIS), which contains information on admissions
17
18 166 and discharges from long-term care facilities [22]. PHN validity will be assessed using the Alberta Health
19
20 167 Care Insurance Plan (AHCIP) Adjusted Population Registry, which contains records of all individuals
21
22 168 registered for healthcare insurance [22,23].

23
24
25 169 Individuals can have multiple laboratory tests over the course of their illness; therefore only the first positive
26
27 170 influenza test during the influenza season will be used, and potential control samples will be selected from
28
29 171 among those who only tested negative for influenza during that influenza season, using the first negative test.
30
31 172 Cases and controls tested <14 days after vaccination will be excluded from the analysis.

32
33
34 173 Influenza vaccination status will be determined from the Influenza Vaccination Registry. The registry
35
36 174 combines data from four databases that record influenza vaccination events (see below).

37
38
39 175 The following administrative data sets will be used in this study.

- 40
41
42 176
- 43 • Alberta Health Immunization and Adverse Reaction to Immunization system (Imm/ARI) contains
44 records of all publicly funded vaccines administered through public health, including influenza
45 177 vaccines administered at mass influenza vaccination clinics, public health clinics, and vaccinations
46 178 administered by public health nurses in long-term care facilities. Data submission is mandatory and
47 179 administered by public health nurses in long-term care facilities. Data submission is mandatory and
48 179 guidelines exist to support complete and accurate vaccination records with descriptions of each,
49 180 including notes [24,25].
50
51
52
53 181
- 54
55
56
57
58
59
60

- 1
2
3 182 • The Supplemental Enhanced Service Event (SESE) database captures physician claims for billing
4
5 183 purposes; International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes,
6
7 184 procedure codes (Canadian Classification of Procedures), codes indicating location of service
8
9 185 delivery, and a number of other administrative elements used to support the payment for each
10
11 186 patient encounter [23,26,27].
- 13
14 187 • Alberta Blue Cross (ABC) administers the pharmacist component of the universal vaccination
15
16 188 program. Pharmacists administering influenza vaccines through this program submit claims to ABC
17
18 189 for each vaccine provided; they are required to submit patient information such as PHN, date of
19
20 190 service, name, and address.
- 21
22 191 • The Pharmaceutical Information Network (PIN) database records dispensed pharmacological
23
24 192 products, regardless of payer, including the rare instances when an influenza vaccine is purchased
25
26 193 rather than administered through the public program (e.g. purchased by travelers prior to the launch
27
28 194 of the public campaign). PIN captures approximately 95% of all dispensed events in the province
29
30 195 [22].
- 31
32 196 • Provincial Vaccine Registry combines influenza vaccinations given in the province and recorded in
33
34 197 four source databases (PIN, ABC, SESE and Imm/ARI).
- 35
36 198 • Alberta Health Care Insurance Plan (AHCIP) Population Registry contains demographic variables,
37
38 199 age, sex, socio-economic status, and geographic zone of residence. Neighbourhood-level socio-
39
40 200 economic status is derived from census dissemination area income quintiles using postal code.
- 41
42 201 • Morbidity and Ambulatory Care Abstracting Reporting (MACAR) system contains ICD-10-CA
43
44 202 diagnostic codes, procedure codes, the date of admission, and date of discharge for every visit to
45
46 203 hospitals, emergency rooms, and outpatient clinics.

47
48
49
50 204 The quality of administrative datasets in Alberta has been extensively reviewed [28–30].

51
52
53 205 Individuals will be considered inpatients if they have at least one physician claim for inpatient services on
54
55 206 the same day as specimen collection or if specimen collection occurred during an inpatient stay; all others

207 will be considered outpatients. Individuals with an immunocompromising condition will be defined as
208 those who have a diagnosis of HIV, who received an organ transplant, or received oral corticosteroids
209 (for ≥ 30 days), antineoplastic agents, or another immunocompromising drug from a community
210 pharmacist in the past 6 months. (Appendix 1 and 2) [31]. HIV diagnosis and ARI will be determined
211 through physician claims and MACAR. Organ transplantation will be determined using MACAR, and
212 immunocompromising drug dispensations will be identified through PIN.

213 **Statistical Analysis**

214 We will use multivariable logistic regression to estimate influenza vaccine effectiveness as $(1 - \text{adjusted OR}) \times$
215 100%. We will estimate VE separately by influenza season and influenza subtype (i.e., A(H3N2),
216 A(H1N1)pdm09, and influenza B) [32]. When there is a large enough sample size in a particular season to
217 provide adequate power, VE will be estimated for specific age groups such as children under the age of 5 and
218 seniors over the age of 65. The following covariates will be included in the adjusted model, regardless of
219 statistical significance: age, sex, socio-economic status, geographic zone of residence, history of
220 immunocompromising comorbidities, healthcare setting (inpatient or outpatient setting), and month of
221 specimen submission within the influenza season. SAS version 9.4 will be used for all statistical analysis (SAS
222 Institute Inc, Cary, NC). VE estimates will be compared to published estimates of VE [6,7,11,13,33,34].
223 As shedding of influenza virus continues for approximately 4-5 days after symptom onset, bias can result if
224 specimens that are collected too long after symptom onset are used [35]. Most studies use a threshold of 7
225 days [36]. To test the robustness of the findings, a sensitivity analysis will be performed; controls will be
226 restricted to those specimens positive for a different respiratory virus (i.e. coronavirus, human respiratory
227 syncytial virus) (As suggested by Sullivan et al 2016).

228 A potential limitation to this study is that the samples utilized here are clinical isolates taken through the
229 course of normal patient care, and are not from a standard case definition as is utilized in some other studies
230 [12]. To test the robustness of the findings, the analysis will be repeated using only cases and controls that

231 were given a diagnosis code for ARI on the same day as specimen collection, as per the SESE database or
232 MACAR. Appendix 3 lists the ICD-9 and ICD-10 codes used to define ARIs.

233

234 **PATIENT AND PUBLIC INVOLVEMENT**

235 Patients and the public were not involved in the design of the study, including the development of the
236 research question, outcomes measures, recruitment to or conduct of the study. The results of the study will
237 be disseminated to the public as deemed appropriate by public health officials.

238

239 **DISCUSSION**

240 This protocol describes the estimation of seasonal influenza VE using specimens collected for routine
241 influenza diagnostics as well as administrative data and vaccination records.

242 A key strength of this approach is the large sample size. This approach allows calculation of near real-time,
243 precise influenza VE estimates weeks prior to the influenza season peak, creating an early warning system for
244 public health if, as in the 2014-2015 season, the vaccine is found to have exceedingly low effectiveness. Early
245 notification of VE can assist public health in determining policies, messaging, and allocation of resources
246 (antiviral agents, staffing emergency departments) to counter a potentially more severe influenza season
247 [36,37]. The large sample size also allows for stratified analyses of VE based on product, age group, or region.

248 Whereas sentinel physician networks rely primarily on self-reported measures of influenza vaccination [33], a
249 significant strength of this study is the use of the near-real-time influenza vaccination registry that contains
250 individual-level, linkable data for most influenza vaccinations administered in the province. Use of this
251 registry reduces the likelihood of recall error and information biases such as social desirability bias and
252 reduces non-differential misclassification, which would bias the odds ratio towards the null, thus
253 underestimating VE [12].

1
2
3 254 Finally, we are certain to capture the results of all respiratory virus testing in the province, as all respiratory
4
5 255 virus testing is centralized at ProvLab and there is limited use of point-of-care testing.
6
7

8 256 There are some limitations to this methodology compared to the traditional method of VE estimation using
9
10 257 sentinel physician networks, because a standardized clinical case definition cannot be applied to determine
11
12 258 study eligibility. A sensitivity analysis restricting to healthcare encounters with a diagnosis code for ARI will
13
14 259 be used as a proxy for a standard case definition.
15
16

17 260 While the inclusion of confounders is important for VE estimate adjustment, not all known confounders can
18
19 261 be measured using administrative data. Frailty has been demonstrated to be a potential confounder of VE
20
21 262 [38–40]. Frailty cannot be included in the multivariable model because no validated indices of frailty
22
23 263 generated from standard administrative data exist at this time. However, this may not affect the results
24
25 264 significantly as a previous study indicated that inclusion of frailty in the multivariate model increased VE
26
27 265 estimates only slightly [41].
28
29

30 266 Laboratory requisitions in Alberta do not contain illness onset date. Ideally this would be used to ensure that
31
32 267 the negative laboratory test results were representative of an acute infectious period and that test-negative
33
34 268 specimens were not collected after viral shedding had ceased. Sullivan et al 2016 have indicated this bias may
35
36 269 be accounted for by selecting influenza test-negative controls that were positive for another respiratory virus.
37
38 270 Requiring controls to be positive for another virus excludes individuals who are tested long after their acute
39
40 271 infectious period. However, a recent systematic review found no differences when using different groups of
41
42 272 controls [42].
43
44

45 273 Comparison of the VE results using administrative data to previously published studies, specifically sentinel
46
47 274 surveillance for the same seasons (2011/12 – 2018/19) will help to identify further areas of refinement.
48
49 275 This approach could successfully allow for the generation of early influenza VE estimates which could
50
51 276 facilitate tailoring of public health messaging and assist in public health operations planning for the peak of
52
53 277 the influenza season.
54
55

56 278
57
58
59
60

1
2
3 **279 ETHICS**
4

5 **280** Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
6
7 **281** under study ID Pro00075997.
8

9 **282**

10
11 **283 LIST OF ABBREVIATIONS**
12

13 **284** ABC – Alberta Blue Cross

14
15 **285** ACCIS – Alberta Continuing Care Information System

16
17 **286** AHCIP – Alberta Health Care Insurance Plan Adjusted Population Registry

18
19 **287** CCI – Canadian Classification of Health Interventions

20
21 **288** CCP – Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures

22
23 **289** ICD-9 – International Classification of Diseases, Ninth Revision

24
25 **290** ICD-10 – International Classification of Diseases, Tenth Revision

26
27 **291** Imm/ARI – Alberta Health Immunization and Adverse Reaction to Immunization system

28
29 **292** MACAR – Morbidity and Ambulatory Care Abstracting Reporting

30
31 **293** PHN – Personal Health Number

32
33 **294** PIN – Pharmaceutical Information Network

34
35 **295** ProvLab – Alberta Provincial Laboratory for Public Health

36
37 **296** RT-PCR – Reverse Transcriptase Polymerase Chain Reaction

38
39 **297** SESE – Supplemental Enhance Service Event

40
41 **298** VE – Vaccine Effectiveness

42
43 **299**

44
45
46 **300 ETHICS APPROVAL AND CONSENT TO PARTICIPATE**
47

48 **301** Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
49
50 **302** under study ID Pro00075997.
51

52
53 **303**

54
55 **304 CONSENT FOR PUBLICATION**
56
57
58
59
60

1
2
3 305 Not applicable
4
5

6 306
7

8
9 307 **AVAILABILITY OF DATA AND MATERIALS**

10
11 308 Not applicable
12

13
14 309

15
16 310 **COMPETING INTERESTS**

17
18 311 The authors declare that they have no competing interests.
19

20
21 312

22
23 313 **FUNDING**

24
25 314 Not applicable
26

27 315
28

29 316 **AUTHOR STATEMENT**

30
31 317 ANS and SJD conceived of and designed the protocol and drafted and revised the manuscript. KS and LS
32 318 planned the original approach, providing guidance on available administrative database resources. SAB and
33 319 JCK made substantial contributions to the design and critically revised the manuscript.
34

35
36 320
37

38 321

39
40 322 **ACKNOWLEDGEMENTS**

41
42 323 The authors would like to acknowledge the staff at Alberta Health Services and ProvLab for their assistance
43 324 in providing administrative and laboratory data sources that could be implemented in this protocol.
44

45 325
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

326 REFERENCES

- 327 1 Mertz D, Tae HK, Johnstone J, *et al*. Populations at risk for severe or complicated influenza illness:
328 systematic review and meta-analysis. *BMJ* 2013;**347**:10.
- 329 2 Alberta Health Services. Alberta Health Services. 2017.
- 330 3 Wong S-S, Webby RJ. Traditional and new influenza vaccines. *Clin Microbiol Rev* 2013;**26**:476–92.
331 doi:10.1128/CMR.00097-12
- 332 4 Skowronski DM, Chambers C, Sabaiduc S, *et al*. A Perfect Storm: Impact of Genomic Variation and
333 Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. *Clin Infect*
334 *Dis An Off Publ Infect Dis Soc Am* 2016;**63**:21–32. doi:10.1093/cid/ciw176
- 335 5 World Health Organization. Influenza Update N ° 309. 2018;**2018**:1–8.
- 336 6 Skowronski DM, De Serres G, Crowcroft NS, *et al*. Association between the 2008-09 seasonal
337 influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies
338 from Canada. *PLoS Med* 2010;**e1000258**. doi:10.1371/journal.pmed.1000258
- 339 7 Chambers C, Skowronski DM, Sabaiduc S, *et al*. Interim estimates of 2015/16 vaccine effectiveness
340 against influenza A(H1N1)pdm09, Canada, February 2016. *Euro Surveill Bull Eur Sur Les Mal Transm =*
341 *Eur Commun Dis Bull* 2016;**21**:30168. doi:10.2807/1560-7917.ES.2016.21.11.30168
- 342 8 Kwong JC, Campitelli MA, Gubbay JB, *et al*. Vaccine effectiveness against laboratory-confirmed
343 influenza hospitalizations among elderly adults during the 2010-2011 season. *Clin Infect Dis An Off Publ*
344 *Infect Dis Soc Am* 2013;**57**:820–7. doi:10.1093/cid/cit404
- 345 9 Orenstein WA, Bernier RH, Dondero TJ, *et al*. Field evaluation of vaccine efficacy. *Bull World Health*
346 *Organ* 1985;**63**:1055–68.
- 347 10 Public Health Agency of Canada. Effectiveness of Vaccine Against Medical Consultation Due to
348 Laboratory-Confirmed Influenza: Results From a Sentinel Physician Pilot Project in British Columbia,
349 2004-2005. *Can Commun Dis Rep* 2005;**31**:181–91.
- 350 11 Skowronski DM, Chambers C, Sabaiduc S, *et al*. Interim estimates of 2016/17 vaccine effectiveness
351 against influenza A(H3N2), Canada, January 2017. *Euro Surveill Bull Eur Sur Les Mal Transm = Eur*
352 *Commun Dis Bull* 2017;**22**. doi:10.2807/1560-7917.ES.2017.22.6.30460
- 353 12 World Health Organization (WHO). Evaluation of influenza vaccine effectiveness: A guide to the
354 design and interpretation of observational studies. 2017;**1**:1–47.
- 355 13 Belongia EA, Simpson MD, King JP, *et al*. Variable influenza vaccine effectiveness by subtype: a
356 systematic review and meta-analysis of test-negative design studies. *Lancet Infectious Dis* 2016;**16**:942–51.
357 doi:10.1016/S1473-3099(16)00129-8
- 358 14 Fathima S, Simmonds K, Invik J, *et al*. Use of laboratory and administrative data to understand the
359 potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in
360 Alberta, Canada. *BMC Infect Dis* 2016;**16**. doi:10.1186/s12879-016-1748-z
- 361 15 Government of Alberta. Alberta Health: History of immunization in Alberta. 2017.
- 362 16 Pabbaraju K, Tokaryk KL, Wong S, *et al*. Comparison of the luminex xTAG respiratory viral panel
363 with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. *J Clin*
364 *Microbiol* 2008;**46**:3056–62. doi:10.1128/JCM.00878-08

- 1
2
3 365 17 Pabbaraju K, Wong S, Wong AA, *et al.* Design and validation of real-time reverse transcription-PCR
4 366 assays for detection of pandemic (H1N1) 2009 virus. *J Clin Microbiol* 2009;**47**:3454–60.
5 367 doi:10.1128/JCM.01103-09
6
7 368 18 Chaudhry A, Bastien N, Li Y, *et al.* Oseltamivir resistance in an influenza A (H3N2) virus isolated
8 369 from an immunocompromised patient during the 2014–2015 influenza season in Alberta, Canada.
9 370 *Influenza Other Respi Viruses* 2016;**10**:532–5. doi:10.1111/irv.12415
10
11 371 19 World Health Organization. Global epidemiological surveillance standards for influenza. 2013.
12
13 372 20 World Health Organization. A Manual for Estimating Disease Burden Associated with Seasonal
14 373 Influenza. 2015.
15
16 374 21 Alberta Health. Alberta Health Seasonal Influenza in Alberta 2016/2017 Summary Report. 2017.
17
18 375 22 Government of Alberta. Overview of Administrative Health Datasets. 2017.
19
20 376 23 Russell ML, Schopflocher DP, Svenson L, *et al.* Secular trends in the epidemiology of shingles in
21 377 Alberta. *Epidemiol Infect* 2007;**135**:908–13.
22
23 378 24 Government of Alberta. Immunization data submission and response guidelines. 2017.
24
25 379 25 MacDonald SE, Dover DC, Simmonds KA, *et al.* Risk of febrile seizures after first dose of measles-
26 380 mumps-rubella- varicella vaccine: A population-based cohort study. *CMAJ* 2014;**186**:824–9.
27 381 doi:10.1503/cmaj.140078
28
29 382 26 Alberta Health. Alberta Health Claims Assessment.
30 383 2017.<https://open.alberta.ca/publications/alberta-health-diagnostic-codes> (accessed 23 Feb 2018).
31
32 384 27 Lix LM, Walker R, Quan H, *et al.* Features of physician services databases in Canada. *Chronic Dis Inj*
33 385 *Can* 2012;**32**:186–93.
34
35 386 28 Hinds A, Lix LM, Smith M, *et al.* Quality of administrative health databases in Canada: a scoping
36 387 review. *Can J Public Heal* 2016;**107**:e56–e61.
37
38 388 29 Shiff NJ, Jama S, Boden C, *et al.* Validation of administrative health data for the pediatric population:
39 389 A scoping review. *BMC Health Serv Res* 2014;**14**. doi:10.1186/1472-6963-14-236
40
41 390 30 Quan H, Smith M, Bartlett-Esquilant G, *et al.* Mining Administrative Health Databases to Advance
42 391 Medical Science: Geographical Considerations and Untapped Potential in Canada. *Can J Cardiol*
43 392 2012;**28**:152–4. doi:10.1016/j.cjca.2012.01.005
44
45 393 31 Schwartz KL, Jembere N, Campitelli MA, *et al.* Using physician billing claims from the Ontario Health
46 394 Insurance Plan to determine individual influenza vaccination status: an updated validation study. *C*
47 395 *Open* 2016;**4**:E470.
48
49 396 32 Sullivan SG, Cowling BJ. ‘Crude Vaccine Effectiveness’ Is a Misleading Term in Test-negative Studies
50 397 of Influenza Vaccine Effectiveness. *Epidemiology* 2015;**26**:e60. doi:10.1097/EDE.0000000000000343
51
52 398 33 Skowronski DM, Janjua NZ, De Serres G, *et al.* Low 2012–13 influenza vaccine effectiveness
53 399 associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating
54 400 viruses. *PLoS One* 2014;**9**:e92153. doi:10.1371/journal.pone.0092153
55
56 401 34 Skowronski DM, Chambers C, Sabaiduc S, *et al.* Interim estimates of 2013/14 vaccine effectiveness
57 402 against influenza A(H1N1)PDM09 from Canada’s sentinel surveillance network, January 2014.

- 1
2
3 403 *Eurosurveillance* 2014;**19**.
- 4
5 404 35 Sullivan SG, Tchetgen Tchetgen J. E, Cowling BJ. Theoretical Basis of the Test-Negative Study
6 405 Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016;**184**:345–53.
7 406 doi:10.1093/aje/kww064
- 8
9 407 36 Orton L, Lloyd-Williams F, Taylor-Robinson D, *et al*. The use of research evidence in public health
10 408 decision making processes: systematic review. *PLoS One*;e21704. doi:10.1371/journal.pone.0021704
- 11
12 409 37 Savel TG, Foldy S. The role of public health informatics in enhancing public health surveillance.
13 410 *MMWR Suppl* 2012;**61**:20–4.
- 14
15 411 38 Nelson JC, Jackson ML, Weiss NS, *et al*. New strategies are needed to improve the accuracy of
16 412 influenza vaccine effectiveness estimates among seniors. *J Clin Epidemiol* 2009;**62**:687–94.
17 413 doi:10.1016/j.jclinepi.2008.06.014
- 18
19 414 39 Jackson LA, Jackson ML, Nelson JC, *et al*. Evidence of bias in estimates of influenza vaccine
20 415 effectiveness in seniors. *Int J Epidemiol* 2006;**35**:337–
21 416 44.[http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
22 417 [=true&db=cmedm&AN=16368725&site=eds-live&scope=site](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
- 23
24 418 40 Jackson LA, Nelson JC, Benson P, *et al*. Functional status is a confounder of the association of
25 419 influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol* 2006;**35**:345–52.
- 26
27 420 41 Talbot HK, Nian H, Chen Q, *et al*. Evaluating the case-positive, control test-negative study design for
28 421 influenza vaccine effectiveness for the frailty bias. *Vaccine* 2016;**34**:1806–9.
29 422 doi:10.1016/j.vaccine.2016.02.037
- 30
31 423 42 Feng S, Cowling BJ, Kelly H, *et al*. Estimating Influenza Vaccine Effectiveness With the Test-
32 424 Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis. *Am J*
33 425 *Epidemiol* 2018;**187**:389–97. doi:10.1093/aje/kwx251

426

Supplementary File - Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Appendix: List of CCP, CCI, and CMG codes utilized to define individuals who have had an organ transplant

CCP Code Description

495	Heart Transplantation
455	Lung Transplant
456	Combined Heart-Lung Transplantation
624	Liver Transplant
675	Transplant of Kidney
648	Transplant of Pancreas

CCI Code Description

1HY85	Transplant, Heart With Lung(S)
1HZ85	Transplant, Heart Nec
1GT85	Transplant, Lung Nec
1GR85	Transplant, Lobe of Lung
1OA85	Transplant, Liver
1PC85	Transplant, Kidney
1OJ85	Transplant, Pancreas
1OK85	Transplant, Pancreas With Duodenum
1NK85	Transplant, Small Intestine
1NP85	Transplant, Small And Large Intestine

CMG 1992 To 2005

175	Heart or Lung Transplant
253	Major Intestinal And Rectal Procedures
310	Liver Transplant
311	Major Pancreatic Procedures
500	Kidney Transplant

CMG 2007 To 2016

110	Lung Transplant
160	Heart Transplant
220	Major Upper Gastrointestinal Reconstruction/Excision
270	Liver/Pancreas/Duodenum Transplant
450	Kidney Transplant

1
2
3 **Appendix: List of drug names and DINs utilized to define immunocompromising conditions**
4
5

DIN	Drug Name	Route of Administration	Strength
00616192	ETOPOSIDE	CAP	50MG
00523410	ETOPOSIDE	IV SOL	20MG/ML
02080036	ETOPOSIDE	IV SOL	20MG/ML
02241182	ETOPOSIDE	IV SOL	20MG/ML
02231622	IRINOTECAN HCL	IV SOL	20MG/ML
02258218	IRINOTECAN HCL	IV SOL	20MG/ML
00015431	VINBLASTINE SULFATE	IV PWS	1MG/ML
00611182	VINCRISTINE SULFATE	IV SOL	1MG/ML
02143305	VINCRISTINE SULFATE	IV SOL	1MG/ML
00004618	BUSULFAN	TAB	2MG
00297763	CARMUSTINE	IV PWS	100MG
09851399	CARMUSTINE	TOP SOL	NOT AVLE
00004626	CHLORAMBUCIL	TAB	2MG
00344915	CYCLOPHOSPHAMIDE	INJ PWS	2GM
00013544	CYCLOPHOSPHAMIDE	IV PWS	200MG
00013552	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241797	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241799	CYCLOPHOSPHAMIDE	IV PWS	1000MG
00013749	CYCLOPHOSPHAMIDE	TAB	50MG
00262676	CYCLOPHOSPHAMIDE	TAB	25MG
00344877	CYCLOPHOSPHAMIDE	TAB	25MG
00344885	CYCLOPHOSPHAMIDE	TAB	50MG
02241795	CYCLOPHOSPHAMIDE	TAB	25MG
02241796	CYCLOPHOSPHAMIDE	TAB	50MG
02063794	ESTRAMUSTINE DISODIUM PHOSPHATE	CAP	140MG
00780278	ESTRAMUSTINE PHOSPHATE	CAP	140MG
00360414	LOMUSTINE	CAP	100MG
00360422	LOMUSTINE	CAP	40MG
00360430	LOMUSTINE	CAP	10MG
00016063	MECHLORETHAMINE	IV PWS	10MG
00004715	MELPHALAN	TAB	2MG
02312794	TEMOZOLOMIDE	CAP	140MG
02312816	TEMOZOLOMIDE	CAP	180MG
02395274	TEMOZOLOMIDE	CAP	20MG
02395282	TEMOZOLOMIDE	CAP	100MG
02395290	TEMOZOLOMIDE	CAP	140MG
02395312	TEMOZOLOMIDE	CAP	250MG
02443473	TEMOZOLOMIDE	CAP	5MG
02443481	TEMOZOLOMIDE	CAP	20MG

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
02443511	TEMOZOLOMIDE	CAP	100MG
02443538	TEMOZOLOMIDE	CAP	140MG
02443554	TEMOZOLOMIDE	CAP	250MG
02241093	TEMOZOLOMIDE	CAP	5MG
02241094	TEMOZOLOMIDE	CAP	20MG
02241095	TEMOZOLOMIDE	CAP	100MG
02241096	TEMOZOLOMIDE	CAP	250MG
02441160	TEMOZOLOMIDE	CAPSULE	5MG
00237035	THIOTEPA	INJ PWS	15MG/ML
02421917	CAPECITABINE	FC TAB	150MG
02421925	CAPECITABINE	FC TAB	500MG
02426757	CAPECITABINE	FC TAB	150MG
02426765	CAPECITABINE	FC TAB	500MG
02400022	CAPECITABINE	TAB	150MG
02400030	CAPECITABINE	TAB	500MG
02238453	CAPECITABINE	TAB	150MG
02238454	CAPECITABINE	TAB	500MG
02022117	CLADRIBINE	IV SOL	1MG
00194727	CYTARABINE	INJ PWS	500MG
00386715	CYTARABINE	INJ PWS	100MG
02167867	CYTARABINE	INJ PWS	100MG
00646296	CYTARABINE	IV PWS	1GM
00646318	CYTARABINE	IV PWS	2GM
02246226	FLUDARABINE PHOSPHATE	TAB	10MG
00012882	FLUOROURACIL	IV SOL	
00330582	FLUOROURACIL	TOP CRM	5%
00465283	HYDROXYUREA	CAP	500MG
02242920	HYDROXYUREA	CAP	500MG
02247937	HYDROXYUREA	CAP	500MG
00004723	MERCAPTOPYRINE	TAB	50MG
02415275	MERCAPTOPYRINE	TABLET	50MG
09857520	METHOTREXATE	INJ SOL	50MG/2ML
02182777	METHOTREXATE	INJ SOL	25MG/ML
02182955	METHOTREXATE	INJ SOL	25MG/ML
00014915	METHOTREXATE	TAB	2.5MG
02170698	METHOTREXATE	TAB	2.5MG
02182750	METHOTREXATE	TAB	10MG
02182963	METHOTREXATE	TAB	2.5MG
02244798	METHOTREXATE	TAB	2.5MG
02398427	METHOTREXATE	VIAL	25MG/ML
00321397	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
00321400	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML

DIN	Drug Name	Route of Administration	Strength
02170663	METHOTREXATE DISODIUM	INJ SOL	50MG/2ML
02170671	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
02182947	METHOTREXATE SODIUM	INJ SOL	10MG/ML
00614335	METHOTREXATE SODIUM	IV SOL	10MG/ML
00874132	METHOTREXATE SODIUM	TAB	2.5MG
02171767	METHOTREXATE SODIUM	TAB	2.5MG
00282081	THIOGUANINE	TAB	40MG
02384256	CRIZOTINIB	CAP	200MG
02384264	CRIZOTINIB	CAP	250MG
02409607	DABRAFENIB	CAP	50MG
02409615	DABRAFENIB	CAP	75MG
02320193	DASATINIB	TAB	100MG
02293129	DASATINIB	TAB	20MG
02293137	DASATINIB	TAB	50MG
02293145	DASATINIB	TAB	70MG
02269007	ERLOTINIB HCL	TAB	25MG
02269015	ERLOTINIB HCL	TAB	100MG
02269023	ERLOTINIB HCL	TAB	150MG
02377705	ERLOTINIB HCL	TABLET	100MG
02377713	ERLOTINIB HCL	TABLET	150MG
02434407	IBRUTINIB	CAP	140MG
09857447	IMATINIB MESYLATE	TAB	100MG
02388006	RUXOLITINIB	TAB	5MG
02388014	RUXOLITINIB	TAB	15MG
02388022	RUXOLITINIB	TAB	20MG
02409658	TRAMETINIB RECOMBINANT	TAB	2MG
01926438	ASPARAGINASE	INJ PWS	10MU
02389649	AXITINIB	TAB	5MG
02389630	AXITINIB	TAB FC	1MG
02262452	BORTEZOMIB	IV PWS	3.5MG
00521183	DACARBAZINE	IV PWS	200MG/VIAL
02154854	DACARBAZINE	IV PWS	200MG
02248676	GEFITINIB	TAB	250MG
02244725	IMATINIB MESYLATE	CAP	100MG
02399806	IMATINIB MESYLATE	FC TAB	100MG
02355337	IMATINIB MESYLATE	TAB	100MG
02355345	IMATINIB MESYLATE	TAB	400MG
02397285	IMATINIB MESYLATE	TAB	100MG
02397293	IMATINIB MESYLATE	TAB	400MG
02399814	IMATINIB MESYLATE	TAB	400MG
02431114	IMATINIB MESYLATE	TAB	100MG
02431122	IMATINIB MESYLATE	TAB	400MG

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
09857448	IMATINIB MESYLATE	TAB	400MG
02253275	IMATINIB MESYLATE	TAB	100MG
02253283	IMATINIB MESYLATE	TAB	400MG
02326442	LAPATINIB DITOSYLATE	TAB	250MG
02315874	NILOTINIB	CAP	200MG
02368250	NILOTINIB	CAP	150MG
02352303	PAZOPANIB HCL	TAB	200MG
00012750	PROCARBAZINE HCL	CAP	50MG
02403390	REGORAFENIB	TAB	40MG
02284227	SORAFENIB TOSYLATE	TAB	200MG
02280795	SUNITINIB MALATE	CAP	12.5MG
02280809	SUNITINIB MALATE	CAP	25MG
02280817	SUNITINIB MALATE	CAP	50MG
02258595	ADALIMUMAB	INJ-SC SOL	40MG
09854785	ADALIMUMAB	INJ-SC SOL	40MG
09857294	ADALIMUMAB	INJ-SC SOL	40MG
09857326	ADALIMUMAB	INJ-SC SOL	40MG
09857327	ADALIMUMAB	INJ-SC SOL	40MG
02130181	ALDESLEUKIN	IV PWS	1.3MG
02331675	CERTOLIZUMAB PEGOL	INJ-SC SOL	200MG/ML
09857394	ETANERCEPT RECOMBINANT	INJ SOL	50MG/ML
02242903	ETANERCEPT RECOMBINANT	INJ-SC PWS	25MG
02274728	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
09857322	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
02233014	GLATIRAMER	INJ-SC PWS	20MG
02245619	GLATIRAMER	INJ-SC SOL	20MG/ML
02324776	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02324784	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02244016	INFLIXIMAB	IV PWS	100MG
09852956	INFLIXIMAB	IV PWS	100MG
02419475	INFLIXIMAB	PWD VIAL	100MG
02239832	INTERFERON	INJ-SC SOL	0.03MG/ML
09852751	INTERFERON	OPH SOL	1MU/ML
02223384	INTERFERON ALFA 2B	INJ PWS	3MMU
02223392	INTERFERON ALFA 2B	INJ PWS	5MMU
02223406	INTERFERON ALFA 2B	INJ PWS	10MMU
02231651	INTERFERON ALFA 2B	INJ PWS	18MMU
00889067	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02223414	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02238674	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
02238675	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
09853995	INTERFERON ALFA 2B	INJ SOL	10MU/VIAL

DIN	Drug Name	Route of Administration	Strength
09854045	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
09854053	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
00705896	INTERFERON ALFA 2B	INJ-SC SOL	3MMU
00705918	INTERFERON ALFA 2B	INJ-SC SOL	5MMU
00705926	INTERFERON ALFA 2B	INJ-SC SOL	10MMU
02240693	INTERFERON ALFA 2B	INJ-SC SOL	18MMU/1.2ML
02240694	INTERFERON ALFA 2B	INJ-SC SOL	30MMU/1.2ML
02240695	INTERFERON ALFA 2B	INJ-SC SOL	60MMU/1.2ML
01911988	INTERFERON ALFA-2A	INJ PWS	3000MU/ML
01911996	INTERFERON ALFA-2A	INJ PWS	9000MU/ML
01912003	INTERFERON ALFA-2A	INJ PWS	6000MU/ML
00812471	INTERFERON ALFA-2A	INJ PWS	6000MU/ML
00812498	INTERFERON ALFA-2A	INJ SOL	6000MU/ML
00812501	INTERFERON ALFA-2A	INJ SOL	3000MU/ML
02217015	INTERFERON ALFA-2A	INJ SOL	3000MU/ML
02217031	INTERFERON ALFA-2A	INJ SOL	6000MU/ML
02217058	INTERFERON ALFA-2A	INJ SOL	9000MU/ML
02217066	INTERFERON ALFA-2A	INJ SOL	18000MU/ML
02019914	INTERFERON ALFA-2A	INJ SOL	9000MU/ML
01959069	INTERFERON ALPHA-N1	INJ SOL	10MU
01959077	INTERFERON ALPHA-N1	INJ SOL	3MU
00709042	INTERFERON ALPHA-N1	INJ SOL	3MU
00709050	INTERFERON ALPHA-N1	INJ SOL	10MU
02169649	INTERFERON BETA	INJ-SC PWS	0.3MG
02237317	INTERFERON BETA 1A	INJ PWS	11MCG
02237318	INTERFERON BETA 1A	INJ PWS	44MCG
02237770	INTERFERON BETA 1A	INJ-IM PWS	30MCG/1.1ML
02269201	INTERFERON BETA 1A	INJ-IM SOL	30MCG/0.5ML
02318253	INTERFERON BETA 1A	INJ-SC SOL	66MCG/1.5ML
02318261	INTERFERON BETA 1A	INJ-SC SOL	132MCG/1.5ML
02237319	INTERFERON BETA 1A	INJ-SC SOL	22MCG/0.5ML
02237320	INTERFERON BETA 1A	INJ-SC SOL	44MCG/0.5ML
09857395	INTERFERON BETA-1A	PREF AUTOINJ PEN	30MCG/0.5ML
02337819	INTERFERON BETA-1B	RECOMBINANT	INJ-SC PWS
00846368	RECOMBINANT	INJ-SC PWS	0.3MG
02234217	LEVAMISOLE HCL	TAB	50MG
02234217	LEVAMISOLE HCL	TAB	50MG
09857505	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
09857505	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248077	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
02248077	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248078	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL
02248078	RECOMBINANT	INJ-SC SOL	180MCG/ML

DIN	Drug Name	Route of Administration	Strength
00258482	BLEOMYCIN SULFATE	INJ PWS	15U
00163899	DAUNORUBICIN HCL	INJ PD	20MG
01926683	DAUNORUBICIN HCL	IV PWS	20MG
00353078	DOXORUBICIN HCL	IV PWS	50MG
00357391	DOXORUBICIN HCL	IV PWS	10MG
00640050	EPIRUBICIN HCL	INJ PWS	10MG
00640069	EPIRUBICIN HCL	IV PWS	50MG
00381799	MITOMYCIN	IV PWS	5MG
00463221	MITOTANE	TAB	500MG
02415992	AFLIBERCEPT	VIAL	40MG/ML
02273993	ALEMTUZUMAB	IV SOL	10MG/ML
02290960	ALEMTUZUMAB	IV SOL	30MG/ML
02270994	BEVACIZUMAB	IV SOL	25MG/ML
09857407	RITUXIMAB	IV SOL	10MG/ML
02241927	RITUXIMAB	IV SOL	10MG/ML

**Appendix: ICD-9 codes and ICD-10 codes utilized to define acute respiratory illness in physician,
ER and hospital encounters.**

Description	ICD-9 Code	ICD-10 Code
Viral infection, unspecified site	079	B34
Viral agents as the cause of diseases classified to other chapters	--	B97 (but not B973 or B977)
Acute nasopharyngitis (common cold)	460	J00
Acute sinusitis	461	J01
Acute pharyngitis	462	J02
Acute tonsillitis	463	J03
Acute laryngitis, tracheitis, epiglottitis, croup	464	J04, J05
Acute upper respiratory infections of multiple or unspecified sites	465	J06
Influenza due to identified novel influenza A virus	488	J09
Influenza	487	J10, J11
Pneumonia, organism unspecified	486	--
Viral pneumonia	480	J12
Bacterial pneumonia	481, 482	J13, J14, J15
Pneumonia due to other specified organism	483	J16
Pneumonia in infectious diseases classified elsewhere	484	J17
Bronchopneumonia, organism unspecified	485	J18
Acute bronchitis and bronchiolitis	466	J20, J21
Unspecified diseases respiratory system	519	J22, J39.8, J39.9
Bronchitis, not specified as acute or chronic	490	J40
Acute respiratory distress syndrome	518.82	J80
Pulmonary edema	518.4	J81
Pleural effusion	510.9, 511.0, 511.1, 511.89	J86.9, J90, R09.1
Respiratory failure	518.81	J96.0, J96.9
Atelectasis	--	J98.10
Pulmonary collapse	518.0	J98.19
Other respiratory disorders	786.00, 786.09	J98.0, J98.4, J98.8, J98.9
Hemoptysis	786.30	R04.2
Cough	786.2	R05
Shortness of breath (dyspnea)	786.02, 786.05, 786.09	R06.0
Stridor	786.1	R06.1
Wheezing	786.07	R06.2
Tachypnea	786.06	R06.4

Description	ICD-9 Code	ICD-10 Code
Chest pain on breathing	786.52	R07.1
Hypoxemia	799.02	R09.0
Respiratory arrest	799.1	R09.2
Abnormal sputum	786.4	R09.3
Nasal congestion	478.19	R09.81
Abnormal chest sounds	786.7	R09.89
Fever	780.60	R50
Chills (without fever)	780.64	R68.0
Sepsis, shock	669.11, 669.12, 669.14,	A41.9, R57.9
	785.50, 785.52, 995.91,	
	995.92	

For peer review only

BMJ Open

Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029708.R2
Article Type:	Protocol
Date Submitted by the Author:	19-Jun-2019
Complete List of Authors:	Scott, Allison; Government of Alberta, Ministry of Health; PolicyWise for Children & Families Buchan, Sarah; Institute for Clinical Evaluative Sciences; Public Health Ontario Kwong, Jeff; Institute for Clinical Evaluative Sciences Drews, Steven; Alberta Provincial Laboratory for Public Health; University of Alberta, Division of Preventive Medicine Simmonds, Kimberley; Alberta Ministry of Health, Epidemiology and Surveillance Svenson, Lawrence; Government of Alberta, Ministry of Health; University of Calgary Cumming School of Medicine, Department of Community Health Sciences
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Public health, Epidemiology
Keywords:	Influenza, Vaccine effectiveness, Case Control, Test-negative, Administrative data, Population level

SCHOLARONE™
Manuscripts

1
2
3 1 **TITLE**

4
5 2 **Using population-wide administrative and laboratory data to estimate type- and subtype-specific**
6 3 **influenza vaccine effectiveness: a surveillance protocol**

7
8 4 Allison N Scott^{1,2,3}

9
10 5 Sarah A Buchan^{4,5,6}

11
12 6 Jeffrey C Kwong^{4,5,6,7,8}

13
14 7 Steven J Drews^{9,10}

15
16 8 Kimberley A Simmonds^{1,11}

17
18 9 Lawrence W Svenson^{1,11, 12, 13}

19
20
21 10

22 11 **Affiliations**

23
24 12 ¹Ministry of Health, Government of Alberta, Edmonton, AB, Canada

25
26 13 ²PolicyWise for Children & Families, Edmonton, AB, Canada

27
28 14 ³Department of Public Health, Concordia University of Edmonton, AB, Canada

29
30 15 ⁴ICES, Toronto, ON, Canada

31
32 16 ⁵Public Health Ontario, Toronto, ON, Canada

33
34 17 ⁶Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

35
36 18 ⁷Department of Family & Community Medicine, University of Toronto, Toronto, ON, Canada

37
38 19 ⁸University Health Network, Toronto, ON, Canada

39
40 20 ⁹The Alberta Provincial Laboratory for Public Health, Edmonton, AB, Canada

41
42 21 ¹⁰Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada

43
44 22 ¹¹ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary,
45 23 AB, Canada

46
47 24 ¹² School of Public Health, University of Alberta, Edmonton, AB, Canada

48
49 25 ¹³ Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada

50
51
52 26

53
54 27 **Corresponding Author:**

55
56 28 Allison N. Scott, Ph.D.

1
2
3 29 PolicyWise for Children & Families
4
5 30 1000, 9925-109 Street NW
6
7 31 Edmonton, Alberta, Canada T5K 2J8
8

9 32

10
11 33 **Email Addresses**

12
13 34 Allison N Scott AScott@policywise.com
14
15 35 Sarah A Buchan Sarah.Buchan@oahpp.ca
16
17 36 Jeffrey C Kwong jeff.kwong@utoronto.ca
18
19 37 Steven J Drews steven.drews@blood.ca
20
21 38 Kimberley A Simmonds kimberley.simmonds@gov.ab.ca
22
23 39 Lawrence W Svenson larry.svenson@gov.ab.ca
24

25 40

26
27 41

28
29 42 **Word Count:** 2,550
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **43 ABSTRACT**

4
5 **44 Introduction**

6
7 45 The appropriateness of using routinely collected laboratory data combined with administrative data for
8
9 46 estimating influenza vaccine effectiveness (VE) is still being explored. This paper outlines a protocol to
10
11 47 estimate influenza VE using linked laboratory and administrative data which could act as a companion to
12
13 48 estimates derived from other methods.

14
15
16 **49 Methods and Analysis**

17
18 50 We will use the test-negative design to estimate VE for each influenza type/subtype and season. Province-
19
20 51 wide individual-level records of positive and negative influenza tests at the Provincial Laboratory for Public
21
22 52 Health in Alberta will be linked, by unique personal health numbers, to administrative databases and
23
24 53 vaccination records held at the Ministry of Health in Alberta to determine covariates and influenza
25
26 54 vaccination status, respectively. Covariates of interests include age, sex, immunocompromising chronic
27
28 55 conditions, and healthcare setting. Cases will be defined based on an individual's first positive influenza test
29
30 56 during the season, and potential controls will be defined based on an individual's first negative influenza test
31
32 57 during the season. One control for each case will be randomly selected based on the week the specimen was
33
34 58 collected. We will estimate vaccine effectiveness using multivariable logistic regression.

35
36
37 **59 Ethics and Dissemination**

38
39 60 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
40
41 61 under study ID Pro00075997. Results will be disseminated by public health officials in Alberta.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 65 **Key Words**
4

5 66 Influenza
6

7 67 Vaccine effectiveness
8

9 68 Case Control
10

11 69 Test-negative
12

13 70 Administrative data
14

15 71 Population-level
16

17 72 Laboratory data
18

19 73 Vaccination database
20

21 74
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 75 **ARTICLE SUMMARY**
4

5 76 **Strengths and limitations of this study**
6

- 7 77 • A strength of this protocol is that it provides near real time estimation of vaccine effectiveness to
8 78 assist public health in allocating resources and determining the appropriate policies and public
9 79 messaging during the influenza season.
10 79
11 80 • Vaccine effectiveness estimates use a test negative design, taking advantage of linked administrative
12 81 health records for the entire population.
13 82
14 82 • While many confounders are included in the vaccine effectiveness estimates, not all known
15 83 confounders can be measured using administrative health data.
16
17 84

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

85 INTRODUCTION

86 Influenza is a respiratory viral disease associated with significant morbidity and mortality globally. Infections
87 range from relatively mild presentations (e.g. cough, sore throat) to severe lower respiratory tract infections
88 (e.g. pneumonia). Severe cases may be associated with hospitalization, intensive care admission, and death;
89 young children, the elderly, and individuals with chronic conditions are at highest risk of severe outcomes[1].
90 In Canada, rates of laboratory-confirmed influenza infections are, on average, approximately 200 cases per
91 100,000 population, with approximately 50% of cases occurring in patients aged ≤ 18 years [2]. The causative
92 agents, influenza A (subtypes H3N2 and H1N1pdm(09)) and influenza B (Yamagata and Victoria lineages),
93 are under strong selective pressure to mutate genetically; significant genetic changes can occur in relatively
94 short periods of time (i.e. < 1 year) [3].

95 Influenza prevention relies, in part, on annual vaccination campaigns. Selection of viral strains for inclusion
96 in the vaccine occurs approximately 9 months prior to the onset of the influenza season; by the time the
97 vaccines are administered, the predominant circulating strains may have mutated to the point such that the
98 effectiveness of the vaccine has diminished or has become completely ineffective [4,5].

99 Influenza VE is commonly estimated using the test-negative design, a variation of the case-control design
100 where cases and controls are selected from a pool of individuals who have been tested for influenza [6–10].
101 Several research groups use sentinel physician networks to recruit patients: influenza testing is performed on
102 patients who meet a case definition for influenza-like illness, and cases and controls are selected from that
103 pool [6–8]. While this has become an established method, there are some limitations to using sentinel
104 physicians. As the physicians are often volunteers, there can be bias in the geographic distribution, leading to
105 clustering of sampling in certain areas and not others. This can lead to inaccuracies as predominant
106 circulating influenza strains vary geographically [7,11]. Immunization information is commonly self-reported,
107 potentially leading to recall and social desirability biases [12]; volunteer physicians may be more likely to have
108 strong views on influenza immunization, potentially making it more difficult for the patient to admit to not
109 being immunized. Finally, as these studies are labour-intensive for clinic staff, physician recruitment is often

1
2
3 110 low, resulting in small sample sizes and wide confidence intervals. Estimates are, therefore, typically available
4
5 111 after the peak of the influenza season, decreasing their usefulness for public health messaging and resource
6
7 112 and operational planning [6–8,11].
8
9

10 113 Using administrative data and routinely collected clinical specimens for estimating VE is currently under
11
12 114 debate [13]. VE estimates generated using linked health administrative and laboratory data in the province
13
14 115 Ontario have been shown to be comparable to previously published estimates[14]. There has been one
15
16 116 published estimate of Alberta-specific vaccine effectiveness using a sentinel surveillance system[11]; however,
17
18 117 because of the small sample size the confidence interval was large, ranging from 8% to 72%. Estimating VE
19
20 118 in a large jurisdiction with near-real-time data on all influenza laboratory testing and influenza vaccination in
21
22 119 the population has the potential to provide more precise and timely VE estimates than has previously been
23
24 120 possible. We present a protocol to estimate influenza VE using individually-linked laboratory and
25
26 121 administrative data.
27
28

29
30 122

31 32 123 **METHODS AND ANALYSIS**

33 34 35 124 **Study Setting:**

36
37
38 125 Alberta is a province in Canada with a publicly-funded universal health care system; each of the 4.25 million
39
40 126 residents is assigned a unique personal health number (PHN) at birth or upon immigration to the province
41
42 127 [15]. The PHN is recorded each time a person accesses the healthcare system, allowing for deterministic
43
44 128 linkage across multiple administrative data sets held by the Ministry of Health.

45
46
47 129 In 2009, influenza vaccination became universally available to all Albertans aged ≥ 6 months, regardless of
48
49 130 comorbidities or other risk conditions [16]. Influenza vaccines are available at no cost to the patient at public
50
51 131 health clinics, pharmacies, physician offices, long-term care facilities, university health centers, and
52
53 132 workplaces. Annual vaccine campaigns begin in October, with approximately 60% of all influenza
54
55 133 vaccinations given by the end of the second week of the campaign. While the peak of influenza activity has
56
57

1
2
3 134 varied widely since 2010, the median influenza peak in Alberta is in mid-January, approximately three months
4
5 135 after vaccination campaigns begin.
6
7

8 136

11 137 **Laboratory methods for influenza A and B detection and influenza A subtyping**

12
13 138 All influenza testing in Alberta is performed at a single diagnostic lab, the Provincial Laboratory for Public
14
15 139 Health (ProvLab) and stored in a single laboratory information system, along with test and patient identifiers.
16
17 140 Clinical specimens (e.g. nasopharyngeal swabs, nasopharyngeal aspirates, bronchoalveolar lavages) are
18
19 141 processed at ProvLab using previously published protocols. Nucleic acid extraction utilizes the easyMAG
20
21 142 extractor and reagents (bioMerieux, St. Laurent, Quebec, Canada)[17]. Nucleic acid from clinical specimens are
22
23 143 then tested using a series of respiratory detection assays as described below. Prior to May 2017, a real-time
24
25 144 influenza A/B reverse-transcriptase PCR (RT-PCR) was used to diagnose influenza using a protocol
26
27 145 previously described [18,19]. After May 2017, ProvLab has been using a Luminex Respiratory Pathogen Panel
28
29 146 for the identification of influenza A (including subtype), influenza B, and other respiratory viruses (e.g.
30
31 147 coronavirus and parainfluenza) [15]. Results of the laboratory testing were imported into specific laboratory
32
33 148 information systems depending on the testing time period.
34
35

36 149

38 150 **Study Design:**

39
40
41 151 We will use the test-negative design to estimate VE. We will estimate VE for the 2011/12 – 2019/20
42
43 152 influenza seasons. The results of all respiratory virus tests conducted at ProvLab will be sent to the Ministry
44
45 153 of Health for deterministic linkage to health administrative databases, in order to determine eligibility for
46
47 154 inclusion in the analysis, influenza vaccination status, and the following covariates: age, sex, socio-economic
48
49 155 status, geographic zone of residence, history of immunocompromising comorbidities, healthcare setting
50
51 156 (inpatient or outpatient setting), and month at the time of specimen submission. The presence of a diagnostic
52
53 157 code for an acute respiratory illness (ARI) at the time of specimen collection will be used in a sensitivity
54
55 158 analysis.
56
57
58
59
60

1
2
3 159 Isolates will be considered eligible for inclusion in the analysis if they met all of the following criteria: a valid
4
5 160 PHN is recorded, the isolate is not from a resident of a long-term care facility, the isolate was collected at
6
7 161 least four weeks after the initiation of the public influenza vaccination program, and the isolate was collected
8
9 162 during the influenza season, as determined using the method recommended by the WHO r [20–22].
10
11

12 163 It is important to ensure that the population has the chance to be exposed to influenza and there is sufficient
13
14 164 time for immunity to the vaccine to be developed. Residence in a long-term care facility will be determined
15
16 165 via the Alberta Continuing Care Information System (ACCIS), which contains information on admissions
17
18 166 and discharges from long-term care facilities [23]. PHN validity will be assessed using the Alberta Health
19
20 167 Care Insurance Plan (AHCIP) Adjusted Population Registry, which contains records of all individuals
21
22 168 registered for healthcare insurance [23,24].
23
24

25 169 Individuals can have multiple laboratory tests over the course of their illness; therefore only the first positive
26
27 170 influenza test during the influenza season will be used, and potential control samples will be selected from
28
29 171 among those who only tested negative for influenza during that influenza season, using the first negative test.
30
31 172 Cases and controls tested <14 days after vaccination will be excluded from the analysis.
32
33

34 173 Influenza vaccination status will be determined from the Influenza Vaccination Registry. The registry
35
36 174 combines data from four databases that record influenza vaccination events (see below).
37
38

39 175 The following administrative data sets will be used in this study.
40
41

- 42 176 • Alberta Health Immunization and Adverse Reaction to Immunization system (Imm/ARI) contains
43
44 177 records of all publicly funded vaccines administered through public health, including influenza
45
46 178 vaccines administered at mass influenza vaccination clinics, public health clinics, and vaccinations
47
48 179 administered by public health nurses in long-term care facilities. Data submission is mandatory and
49
50 180 guidelines exist to support complete and accurate vaccination records with descriptions of each,
51
52 181 including notes [25,26].
53
54
55
56
57
58
59
60

- 1
2
3 182 • The Supplemental Enhanced Service Event (SESE) database captures physician claims for billing
4
5 183 purposes; International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes,
6
7 184 procedure codes (Canadian Classification of Procedures), codes indicating location of service
8
9 185 delivery, and a number of other administrative elements used to support the payment for each
10
11 186 patient encounter [24,27,28].
- 13
14 187 • Alberta Blue Cross (ABC) administers the pharmacist component of the universal vaccination
15
16 188 program. Pharmacists administering influenza vaccines through this program submit claims to ABC
17
18 189 for each vaccine provided; they are required to submit patient information such as PHN, date of
19
20 190 service, name, and address.
- 21
22 191 • The Pharmaceutical Information Network (PIN) database records dispensed pharmacological
23
24 192 products, regardless of payer, including the rare instances when an influenza vaccine is purchased
25
26 193 rather than administered through the public program (e.g. purchased by travelers prior to the launch
27
28 194 of the public campaign). PIN captures approximately 95% of all dispensed events in the province
29
30 195 [23].
- 31
32 196 • Provincial Vaccine Registry combines influenza vaccinations given in the province and recorded in
33
34 197 four source databases (PIN, ABC, SESE and Imm/ARI).
- 35
36 198 • Alberta Health Care Insurance Plan (AHCIP) Population Registry contains demographic variables,
37
38 199 age, sex, socio-economic status, and geographic zone of residence. Neighbourhood-level socio-
39
40 200 economic status is derived from census dissemination area income quintiles using postal code.
- 41
42 201 • Morbidity and Ambulatory Care Abstracting Reporting (MACAR) system contains ICD-10-CA
43
44 202 diagnostic codes, procedure codes, the date of admission, and date of discharge for every visit to
45
46 203 hospitals, emergency rooms, and outpatient clinics.

47
48
49
50 204 The quality of administrative datasets in Alberta has been extensively reviewed [29–31].

51
52
53 205 Individuals will be considered inpatients if they have at least one physician claim for inpatient services on
54
55 206 the same day as specimen collection or if specimen collection occurred during an inpatient stay; all others

1
2
3 207 will be considered outpatients. Individuals with an immunocompromising condition will be defined as
4
5 208 those who have a diagnosis of HIV, who received an organ transplant, or received oral corticosteroids
6
7 209 (for ≥ 30 days), antineoplastic agents, or another immunocompromising drug from a community
8
9 210 pharmacist in the past 6 months. (Appendix 1 and 2) [32]. HIV diagnosis and ARI will be determined
10
11 211 through physician claims and MACAR. Organ transplantation will be determined using MACAR, and
12
13 212 immunocompromising drug dispensations will be identified through PIN.

16 213 **Statistical Analysis**

17
18
19 214 We will use multivariable logistic regression to estimate influenza vaccine effectiveness as $(1 - \text{adjusted OR}) \times$
20
21 215 100%. We will estimate VE separately by influenza season and influenza subtype (i.e., A(H3N2),
22
23 216 A(H1N1)pdm09, and influenza B) [33]. When there is a large enough sample size in a particular season to
24
25 217 provide adequate power, VE will be estimated for specific age groups such as children under the age of 5 and
26
27 218 seniors over the age of 65. The following covariates will be included in the adjusted model, regardless of
28
29 219 statistical significance: age, sex, socio-economic status, geographic zone of residence, history of
30
31 220 immunocompromising comorbidities, healthcare setting (inpatient or outpatient setting), and month of
32
33 221 specimen submission within the influenza season. SAS version 9.4 will be used for all statistical analysis (SAS
34
35 222 Institute Inc, Cary, NC). VE estimates will be compared to published estimates of VE [6,7,11,13,34,35].
36
37
38 223 As shedding of influenza virus continues for approximately 4-5 days after symptom onset, bias can result if
39
40 224 specimens that are collected too long after symptom onset are used [36]. Most studies use a threshold of 7
41
42 225 days [37]. To test the robustness of the findings, a sensitivity analysis will be performed; controls will be
43
44 226 restricted to those specimens positive for a different respiratory virus (i.e. coronavirus, human respiratory
45
46 227 syncytial virus) (As suggested by Sullivan et al 2016).

47
48
49
50 228 A potential limitation to this study is that the samples utilized here are clinical isolates taken through the
51
52 229 course of normal patient care, and are not from a standard case definition as is utilized in some other studies
53
54 230 [12]. To test the robustness of the findings, the analysis will be repeated using only cases and controls that

1
2
3 231 were given a diagnosis code for ARI on the same day as specimen collection, as per the SESE database or
4
5 232 MACAR. Appendix 3 lists the ICD-9 and ICD-10 codes used to define ARIs.
6
7

8 233
9

10 234 **PATIENT AND PUBLIC INVOLVEMENT**

11
12
13
14 235 Patients and the public were not involved in the design of the study, including the development of the
15
16 236 research question, outcomes measures, recruitment to or conduct of the study. The results of the study will
17
18 237 be disseminated to the public as deemed appropriate by public health officials.
19
20

21 238
22

23 239 **DISCUSSION**

24
25
26 240 This protocol describes the estimation of seasonal influenza VE using specimens collected for routine
27
28 241 influenza diagnostics as well as administrative data and vaccination records.
29

30
31 242 A key strength of this approach is the large sample size. This approach allows calculation of near real-time,
32
33 243 precise influenza VE estimates weeks prior to the influenza season peak, creating an early warning system for
34
35 244 public health if, as in the 2014-2015 season, the vaccine is found to have exceedingly low effectiveness. Early
36
37 245 notification of VE can assist public health in determining policies, messaging, and allocation of resources
38
39 246 (antiviral agents, staffing emergency departments) to counter a potentially more severe influenza season
40
41 247 [37,38]. The large sample size also allows for stratified analyses of VE based on product, age group, or region.
42
43

44 248 Whereas sentinel physician networks rely primarily on self-reported measures of influenza vaccination [34], a
45
46 249 significant strength of this study is the use of the near-real-time influenza vaccination registry that contains
47
48 250 individual-level, linkable data for most influenza vaccinations administered in the province. Use of this
49
50 251 registry reduces the likelihood of recall error and information biases such as social desirability bias and
51
52 252 reduces non-differential misclassification, which would bias the odds ratio towards the null, thus
53
54 253 underestimating VE [12].
55
56
57
58
59
60

1
2
3 254 Finally, we are certain to capture the results of all respiratory virus testing in the province, as all respiratory
4
5 255 virus testing is centralized at ProvLab and there is limited use of point-of-care testing.
6
7

8 256 There are some limitations to this methodology compared to the traditional method of VE estimation using
9
10 257 sentinel physician networks, because a standardized clinical case definition cannot be applied to determine
11
12 258 study eligibility. A sensitivity analysis restricting to healthcare encounters with a diagnosis code for ARI will
13
14 259 be used as a proxy for a standard case definition.
15
16

17 260 While the inclusion of confounders is important for VE estimate adjustment, not all known confounders can
18
19 261 be measured using administrative data. Frailty has been demonstrated to be a potential confounder of VE
20
21 262 [39–41]. Frailty cannot be included in the multivariable model because no validated indices of frailty
22
23 263 generated from standard administrative data exist at this time. However, this may not affect the results
24
25 264 significantly as a previous study indicated that inclusion of frailty in the multivariate model increased VE
26
27 265 estimates only slightly [42].
28
29

30 266 Laboratory requisitions in Alberta do not contain illness onset date. Ideally this would be used to ensure that
31
32 267 the negative laboratory test results were representative of an acute infectious period and that test-negative
33
34 268 specimens were not collected after viral shedding had ceased. Sullivan et al 2016 have indicated this bias may
35
36 269 be accounted for by selecting influenza test-negative controls that were positive for another respiratory virus.
37
38 270 Requiring controls to be positive for another virus excludes individuals who are tested long after their acute
39
40 271 infectious period. However, a recent systematic review found no differences when using different groups of
41
42 272 controls [43].
43
44

45 273 Comparison of the VE results using administrative data to previously published studies, specifically sentinel
46
47 274 surveillance for the same seasons (2011/12 – 2018/19) will help to identify further areas of refinement.
48
49 275 This approach could successfully allow for the generation of early influenza VE estimates which could
50
51 276 facilitate tailoring of public health messaging and assist in public health operations planning for the peak of
52
53 277 the influenza season.
54
55

56 278
57
58
59
60

1
2
3 **279 ETHICS**
4

5 **280** Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
6
7 **281** under study ID Pro00075997.
8

9 **282**

10
11 **283 LIST OF ABBREVIATIONS**
12

13 **284** ABC – Alberta Blue Cross
14

15 **285** ACCIS – Alberta Continuing Care Information System
16

17 **286** AHCIP – Alberta Health Care Insurance Plan Adjusted Population Registry
18

19 **287** CCI – Canadian Classification of Health Interventions
20

21 **288** CCP – Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures
22

23 **289** ICD-9 – International Classification of Diseases, Ninth Revision
24

25 **290** ICD-10 – International Classification of Diseases, Tenth Revision
26

27 **291** Imm/ARI – Alberta Health Immunization and Adverse Reaction to Immunization system
28

29 **292** MACAR – Morbidity and Ambulatory Care Abstracting Reporting
30

31 **293** PHN – Personal Health Number
32

33 **294** PIN – Pharmaceutical Information Network
34

35 **295** ProvLab – Alberta Provincial Laboratory for Public Health
36

37 **296** RT-PCR – Reverse Transcriptase Polymerase Chain Reaction
38

39 **297** SESE – Supplemental Enhance Service Event
40

41 **298** VE – Vaccine Effectiveness
42

43 **299**
44
45

46 **300 ETHICS APPROVAL AND CONSENT TO PARTICIPATE**
47

48 **301** Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
49
50 **302** under study ID Pro00075997.
51

52 **303**
53

54 **304 CONSENT FOR PUBLICATION**
55
56
57
58
59
60

1
2
3 305 Not applicable
4
5

6 306
7

8
9 307 **AVAILABILITY OF DATA AND MATERIALS**

10
11 308 Not applicable
12

13
14 309

15
16 310 **COMPETING INTERESTS**

17
18 311 The authors declare that they have no competing interests.
19

20
21 312

22
23 313 **FUNDING**

24
25 314 Not applicable
26

27 315

28
29 316 **AUTHOR STATEMENT**

30
31 317 ANS and SJD conceived of and designed the protocol and drafted and revised the manuscript. KS and LS
32 318 planned the original approach, providing guidance on available administrative database resources. SAB and
33 319 JCK made substantial contributions to the design and critically revised the manuscript.
34

35
36 320

37
38 321

39
40 322 **ACKNOWLEDGEMENTS**

41
42 323 The authors would like to acknowledge the staff at Alberta Health Services and ProvLab for their assistance
43 324 in providing administrative and laboratory data sources that could be implemented in this protocol.
44

45 325 **LICENCE STATEMENT**

46
47 326 * I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as
48 327 defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
49 328 contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence
50 329 shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or
51 330 employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free
52 331 basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by
53 332 BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and
54
55
56
57
58
59
60

1
2
3 333 to exploit all rights, as set out in our [licence](#).
4 334

5
6 335 The Submitting Author accepts and understands that any supply made under these terms is made by
7 336 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a
8 337 postgraduate student of an affiliated institution which is paying any applicable article publishing charge
9 338 (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an
10 339 Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall
11 340 be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#)
12 341 licence will apply to this Work are set out in our licence referred to above.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

342 REFERENCES

- 343 1 Mertz D, Tae HK, Johnstone J, *et al*. Populations at risk for severe or complicated influenza illness:
344 systematic review and meta-analysis. *BMJ* 2013;**347**:10.
- 345 2 Alberta Health Services. Alberta Health Services. 2017.
- 346 3 Wong S-S, Webby RJ. Traditional and new influenza vaccines. *Clin Microbiol Rev* 2013;**26**:476–92.
347 doi:10.1128/CMR.00097-12
- 348 4 Skowronski DM, Chambers C, Sabaiduc S, *et al*. A Perfect Storm: Impact of Genomic Variation and
349 Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. *Clin Infect*
350 *Dis An Off Publ Infect Dis Soc Am* 2016;**63**:21–32. doi:10.1093/cid/ciw176
- 351 5 World Health Organization. Influenza Update N ° 309. 2018;**2018**:1–8.
- 352 6 Skowronski DM, De Serres G, Crowcroft NS, *et al*. Association between the 2008-09 seasonal
353 influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies
354 from Canada. *PLoS Med* 2010;**e1000258**. doi:10.1371/journal.pmed.1000258
- 355 7 Chambers C, Skowronski DM, Sabaiduc S, *et al*. Interim estimates of 2015/16 vaccine effectiveness
356 against influenza A(H1N1)pdm09, Canada, February 2016. *Euro Surveill Bull Eur Sur Les Mal Transm =*
357 *Eur Commun Dis Bull* 2016;**21**:30168. doi:10.2807/1560-7917.ES.2016.21.11.30168
- 358 8 Kwong JC, Campitelli MA, Gubbay JB, *et al*. Vaccine effectiveness against laboratory-confirmed
359 influenza hospitalizations among elderly adults during the 2010-2011 season. *Clin Infect Dis An Off Publ*
360 *Infect Dis Soc Am* 2013;**57**:820–7. doi:10.1093/cid/cit404
- 361 9 Orenstein WA, Bernier RH, Dondero TJ, *et al*. Field evaluation of vaccine efficacy. *Bull World Health*
362 *Organ* 1985;**63**:1055–68.
- 363 10 Public Health Agency of Canada. Effectiveness of Vaccine Against Medical Consultation Due to
364 Laboratory-Confirmed Influenza: Results From a Sentinel Physician Pilot Project in British Columbia,
365 2004-2005. *Can Commun Dis Rep* 2005;**31**:181–91.
- 366 11 Skowronski DM, Chambers C, Sabaiduc S, *et al*. Interim estimates of 2016/17 vaccine effectiveness
367 against influenza A(H3N2), Canada, January 2017. *Euro Surveill Bull Eur Sur Les Mal Transm = Eur*
368 *Commun Dis Bull* 2017;**22**. doi:10.2807/1560-7917.ES.2017.22.6.30460
- 369 12 World Health Organization (WHO). Evaluation of influenza vaccine effectiveness: A guide to the
370 design and interpretation of observational studies. 2017;**1**:1–47.
- 371 13 Belongia EA, Simpson MD, King JP, *et al*. Variable influenza vaccine effectiveness by subtype: a
372 systematic review and meta-analysis of test-negative design studies. *Lancet Infectious Dis* 2016;**16**:942–51.
373 doi:10.1016/S1473-3099(16)00129-8
- 374 14 Kwong JC, Buchan SA, Chung H, *et al*. Can routinely collected laboratory and health administrative
375 data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other
376 Respiratory Viruses Research (FOREVER) Cohort. *Vaccine* Published Online First: 17 June 2019.
377 doi:10.1016/j.vaccine.2019.06.011
- 378 15 Fathima S, Simmonds K, Invik J, *et al*. Use of laboratory and administrative data to understand the
379 potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in
380 Alberta, Canada. *BMC Infect Dis* 2016;**16**. doi:10.1186/s12879-016-1748-z

- 1
2
3 381 16 Government of Alberta. Alberta Health: History of immunization in Alberta. 2017.
4
5 382 17 Pabbaraju K, Tokaryk KL, Wong S, *et al*. Comparison of the luminex xTAG respiratory viral panel
6 383 with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. *J Clin*
7 384 *Microbiol* 2008;**46**:3056–62. doi:10.1128/JCM.00878-08
8
9 385 18 Pabbaraju K, Wong S, Wong AA, *et al*. Design and validation of real-time reverse transcription-PCR
10 386 assays for detection of pandemic (H1N1) 2009 virus. *J Clin Microbiol* 2009;**47**:3454–60.
11 387 doi:10.1128/JCM.01103-09
12
13 388 19 Chaudhry A, Bastien N, Li Y, *et al*. Oseltamivir resistance in an influenza A (H3N2) virus isolated
14 389 from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
15 390 *Influenza Other Respi Viruses* 2016;**10**:532–5. doi:10.1111/irv.12415
16
17 391 20 World Health Organization. Global epidemiological surveillance standards for influenza. 2013.
18
19 392 21 World Health Organization. A Manual for Estimating Disease Burden Associated with Seasonal
20 393 Influenza. 2015.
21
22 394 22 Alberta Health. Alberta Health Seasonal Influenza in Alberta 2016/2017 Summary Report. 2017.
23
24 395 23 Government of Alberta. Overview of Administrative Health Datasets. 2017.
25
26 396 24 Russell ML, Schopflocher DP, Svenson L, *et al*. Secular trends in the epidemiology of shingles in
27 397 Alberta. *Epidemiol Infect* 2007;**135**:908–13.
28
29 398 25 Government of Alberta. Immunization data submission and response guidelines. 2017.
30
31 399 26 MacDonald SE, Dover DC, Simmonds KA, *et al*. Risk of febrile seizures after first dose of measles-
32 400 mumps-rubella- varicella vaccine: A population-based cohort study. *CMAJ* 2014;**186**:824–9.
33 401 doi:10.1503/cmaj.140078
34
35 402 27 Alberta Health. Alberta Health Claims Assessment.
36 403 2017. <https://open.alberta.ca/publications/alberta-health-diagnostic-codes> (accessed 23 Feb 2018).
37
38 404 28 Lix LM, Walker R, Quan H, *et al*. Features of physician services databases in Canada. *Chronic Dis Inj*
39 405 *Can* 2012;**32**:186–93.
40
41 406 29 Hinds A, Lix LM, Smith M, *et al*. Quality of administrative health databases in Canada: a scoping
42 407 review. *Can J Public Heal* 2016;**107**:e56--e61.
43
44 408 30 Shiff NJ, Jama S, Boden C, *et al*. Validation of administrative health data for the pediatric population:
45 409 A scoping review. *BMC Health Serv Res* 2014;**14**. doi:10.1186/1472-6963-14-236
46
47 410 31 Quan H, Smith M, Bartlett-Esquilant G, *et al*. Mining Administrative Health Databases to Advance
48 411 Medical Science: Geographical Considerations and Untapped Potential in Canada. *Can J Cardiol*
49 412 2012;**28**:152–4. doi:10.1016/j.cjca.2012.01.005
50
51 413 32 Schwartz KL, Jembere N, Campitelli MA, *et al*. Using physician billing claims from the Ontario Health
52 414 Insurance Plan to determine individual influenza vaccination status: an updated validation study. *C*
53 415 *Open* 2016;**4**:E470.
54
55 416 33 Sullivan SG, Cowling BJ. ‘Crude Vaccine Effectiveness’ Is a Misleading Term in Test-negative Studies
56 417 of Influenza Vaccine Effectiveness. *Epidemiology* 2015;**26**:e60. doi:10.1097/EDE.0000000000000343
57
58
59
60

- 1
2
3 418 34 Skowronski DM, Janjua NZ, De Serres G, *et al.* Low 2012-13 influenza vaccine effectiveness
4 419 associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating
5 420 viruses. *PLoS One* 2014;**9**:e92153. doi:10.1371/journal.pone.0092153
6
7 421 35 Skowronski DM, Chambers C, Sabaiduc S, *et al.* Interim estimates of 2013/14 vaccine effectiveness
8 422 against influenza A(H1N1)PDM09 from Canada's sentinel surveillance network, January 2014.
9 423 *Eurosurveillance* 2014;**19**.
10
11 424 36 Sullivan SG, Tchetgen Tchetgen J. E, Cowling BJ. Theoretical Basis of the Test-Negative Study
12 425 Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016;**184**:345–53.
13 426 doi:10.1093/aje/kww064
14
15 427 37 Orton L, Lloyd-Williams F, Taylor-Robinson D, *et al.* The use of research evidence in public health
16 428 decision making processes: systematic review. *PLoS One*;e21704. doi:10.1371/journal.pone.0021704
17
18 429 38 Savel TG, Foldy S. The role of public health informatics in enhancing public health surveillance.
19 430 *MMWR Suppl* 2012;**61**:20–4.
20
21 431 39 Nelson JC, Jackson ML, Weiss NS, *et al.* New strategies are needed to improve the accuracy of
22 432 influenza vaccine effectiveness estimates among seniors. *J Clin Epidemiol* 2009;**62**:687–94.
23 433 doi:10.1016/j.jclinepi.2008.06.014
24
25 434 40 Jackson LA, Jackson ML, Nelson JC, *et al.* Evidence of bias in estimates of influenza vaccine
26 435 effectiveness in seniors. *Int J Epidemiol* 2006;**35**:337–
27 436 44.[http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
28 437 [=true&db=cmedm&AN=16368725&site=eds-live&scope=site](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
29
30 438 41 Jackson LA, Nelson JC, Benson P, *et al.* Functional status is a confounder of the association of
31 439 influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol* 2006;**35**:345–52.
32
33 440 42 Talbot HK, Nian H, Chen Q, *et al.* Evaluating the case-positive, control test-negative study design for
34 441 influenza vaccine effectiveness for the frailty bias. *Vaccine* 2016;**34**:1806–9.
35 442 doi:10.1016/j.vaccine.2016.02.037
36
37 443 43 Feng S, Cowling BJ, Kelly H, *et al.* Estimating Influenza Vaccine Effectiveness With the Test-
38 444 Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis. *Am J*
39 445 *Epidemiol* 2018;**187**:389–97. doi:10.1093/aje/kwx251
40 446
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary File - Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Appendix: List of CCP, CCI, and CMG codes utilized to define individuals who have had an organ transplant

CCP Code Description

495	Heart Transplantation
455	Lung Transplant
456	Combined Heart-Lung Transplantation
624	Liver Transplant
675	Transplant of Kidney
648	Transplant of Pancreas

CCI Code Description

1HY85	Transplant, Heart With Lung(S)
1HZ85	Transplant, Heart Nec
1GT85	Transplant, Lung Nec
1GR85	Transplant, Lobe of Lung
1OA85	Transplant, Liver
1PC85	Transplant, Kidney
1OJ85	Transplant, Pancreas
1OK85	Transplant, Pancreas With Duodenum
1NK85	Transplant, Small Intestine
1NP85	Transplant, Small And Large Intestine

CMG 1992 To 2005

175	Heart or Lung Transplant
253	Major Intestinal And Rectal Procedures
310	Liver Transplant
311	Major Pancreatic Procedures
500	Kidney Transplant

CMG 2007 To 2016

110	Lung Transplant
160	Heart Transplant
220	Major Upper Gastrointestinal Reconstruction/Excision
270	Liver/Pancreas/Duodenum Transplant
450	Kidney Transplant

1
2
3 **Appendix: List of drug names and DINs utilized to define immunocompromising conditions**
4
5

DIN	Drug Name	Route of Administration	Strength
00616192	ETOPOSIDE	CAP	50MG
00523410	ETOPOSIDE	IV SOL	20MG/ML
02080036	ETOPOSIDE	IV SOL	20MG/ML
02241182	ETOPOSIDE	IV SOL	20MG/ML
02231622	IRINOTECAN HCL	IV SOL	20MG/ML
02258218	IRINOTECAN HCL	IV SOL	20MG/ML
00015431	VINBLASTINE SULFATE	IV PWS	1MG/ML
00611182	VINCRISTINE SULFATE	IV SOL	1MG/ML
02143305	VINCRISTINE SULFATE	IV SOL	1MG/ML
00004618	BUSULFAN	TAB	2MG
00297763	CARMUSTINE	IV PWS	100MG
09851399	CARMUSTINE	TOP SOL	NOT AVLE
00004626	CHLORAMBUCIL	TAB	2MG
00344915	CYCLOPHOSPHAMIDE	INJ PWS	2GM
00013544	CYCLOPHOSPHAMIDE	IV PWS	200MG
00013552	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241797	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241799	CYCLOPHOSPHAMIDE	IV PWS	1000MG
00013749	CYCLOPHOSPHAMIDE	TAB	50MG
00262676	CYCLOPHOSPHAMIDE	TAB	25MG
00344877	CYCLOPHOSPHAMIDE	TAB	25MG
00344885	CYCLOPHOSPHAMIDE	TAB	50MG
02241795	CYCLOPHOSPHAMIDE	TAB	25MG
02241796	CYCLOPHOSPHAMIDE	TAB	50MG
02063794	ESTRAMUSTINE DISODIUM PHOSPHATE	CAP	140MG
00780278	ESTRAMUSTINE PHOSPHATE	CAP	140MG
00360414	LOMUSTINE	CAP	100MG
00360422	LOMUSTINE	CAP	40MG
00360430	LOMUSTINE	CAP	10MG
00016063	MECHLORETHAMINE	IV PWS	10MG
00004715	MELPHALAN	TAB	2MG
02312794	TEMOZOLOMIDE	CAP	140MG
02312816	TEMOZOLOMIDE	CAP	180MG
02395274	TEMOZOLOMIDE	CAP	20MG
02395282	TEMOZOLOMIDE	CAP	100MG
02395290	TEMOZOLOMIDE	CAP	140MG
02395312	TEMOZOLOMIDE	CAP	250MG
02443473	TEMOZOLOMIDE	CAP	5MG
02443481	TEMOZOLOMIDE	CAP	20MG

DIN	Drug Name	Route of Administration	Strength
02443511	TEMOZOLOMIDE	CAP	100MG
02443538	TEMOZOLOMIDE	CAP	140MG
02443554	TEMOZOLOMIDE	CAP	250MG
02241093	TEMOZOLOMIDE	CAP	5MG
02241094	TEMOZOLOMIDE	CAP	20MG
02241095	TEMOZOLOMIDE	CAP	100MG
02241096	TEMOZOLOMIDE	CAP	250MG
02441160	TEMOZOLOMIDE	CAPSULE	5MG
00237035	THIOTEPA	INJ PWS	15MG/ML
02421917	CAPECITABINE	FC TAB	150MG
02421925	CAPECITABINE	FC TAB	500MG
02426757	CAPECITABINE	FC TAB	150MG
02426765	CAPECITABINE	FC TAB	500MG
02400022	CAPECITABINE	TAB	150MG
02400030	CAPECITABINE	TAB	500MG
02238453	CAPECITABINE	TAB	150MG
02238454	CAPECITABINE	TAB	500MG
02022117	CLADRIBINE	IV SOL	1MG
00194727	CYTARABINE	INJ PWS	500MG
00386715	CYTARABINE	INJ PWS	100MG
02167867	CYTARABINE	INJ PWS	100MG
00646296	CYTARABINE	IV PWS	1GM
00646318	CYTARABINE	IV PWS	2GM
02246226	FLUDARABINE PHOSPHATE	TAB	10MG
00012882	FLUOROURACIL	IV SOL	
00330582	FLUOROURACIL	TOP CRM	5%
00465283	HYDROXYUREA	CAP	500MG
02242920	HYDROXYUREA	CAP	500MG
02247937	HYDROXYUREA	CAP	500MG
00004723	MERCAPTOPYRINE	TAB	50MG
02415275	MERCAPTOPYRINE	TABLET	50MG
09857520	METHOTREXATE	INJ SOL	50MG/2ML
02182777	METHOTREXATE	INJ SOL	25MG/ML
02182955	METHOTREXATE	INJ SOL	25MG/ML
00014915	METHOTREXATE	TAB	2.5MG
02170698	METHOTREXATE	TAB	2.5MG
02182750	METHOTREXATE	TAB	10MG
02182963	METHOTREXATE	TAB	2.5MG
02244798	METHOTREXATE	TAB	2.5MG
02398427	METHOTREXATE	VIAL	25MG/ML
00321397	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
00321400	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
02170663	METHOTREXATE DISODIUM	INJ SOL	50MG/2ML
02170671	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
02182947	METHOTREXATE SODIUM	INJ SOL	10MG/ML
00614335	METHOTREXATE SODIUM	IV SOL	10MG/ML
00874132	METHOTREXATE SODIUM	TAB	2.5MG
02171767	METHOTREXATE SODIUM	TAB	2.5MG
00282081	THIOGUANINE	TAB	40MG
02384256	CRIZOTINIB	CAP	200MG
02384264	CRIZOTINIB	CAP	250MG
02409607	DABRAFENIB	CAP	50MG
02409615	DABRAFENIB	CAP	75MG
02320193	DASATINIB	TAB	100MG
02293129	DASATINIB	TAB	20MG
02293137	DASATINIB	TAB	50MG
02293145	DASATINIB	TAB	70MG
02269007	ERLOTINIB HCL	TAB	25MG
02269015	ERLOTINIB HCL	TAB	100MG
02269023	ERLOTINIB HCL	TAB	150MG
02377705	ERLOTINIB HCL	TABLET	100MG
02377713	ERLOTINIB HCL	TABLET	150MG
02434407	IBRUTINIB	CAP	140MG
09857447	IMATINIB MESYLATE	TAB	100MG
02388006	RUXOLITINIB	TAB	5MG
02388014	RUXOLITINIB	TAB	15MG
02388022	RUXOLITINIB	TAB	20MG
02409658	TRAMETINIB RECOMBINANT	TAB	2MG
01926438	ASPARAGINASE	INJ PWS	10MU
02389649	AXITINIB	TAB	5MG
02389630	AXITINIB	TAB FC	1MG
02262452	BORTEZOMIB	IV PWS	3.5MG
00521183	DACARBAZINE	IV PWS	200MG/VIAL
02154854	DACARBAZINE	IV PWS	200MG
02248676	GEFITINIB	TAB	250MG
02244725	IMATINIB MESYLATE	CAP	100MG
02399806	IMATINIB MESYLATE	FC TAB	100MG
02355337	IMATINIB MESYLATE	TAB	100MG
02355345	IMATINIB MESYLATE	TAB	400MG
02397285	IMATINIB MESYLATE	TAB	100MG
02397293	IMATINIB MESYLATE	TAB	400MG
02399814	IMATINIB MESYLATE	TAB	400MG
02431114	IMATINIB MESYLATE	TAB	100MG
02431122	IMATINIB MESYLATE	TAB	400MG

DIN	Drug Name	Route of Administration	Strength
09857448	IMATINIB MESYLATE	TAB	400MG
02253275	IMATINIB MESYLATE	TAB	100MG
02253283	IMATINIB MESYLATE	TAB	400MG
02326442	LAPATINIB DITOSYLATE	TAB	250MG
02315874	NILOTINIB	CAP	200MG
02368250	NILOTINIB	CAP	150MG
02352303	PAZOPANIB HCL	TAB	200MG
00012750	PROCARBAZINE HCL	CAP	50MG
02403390	REGORAFENIB	TAB	40MG
02284227	SORAFENIB TOSYLATE	TAB	200MG
02280795	SUNITINIB MALATE	CAP	12.5MG
02280809	SUNITINIB MALATE	CAP	25MG
02280817	SUNITINIB MALATE	CAP	50MG
02258595	ADALIMUMAB	INJ-SC SOL	40MG
09854785	ADALIMUMAB	INJ-SC SOL	40MG
09857294	ADALIMUMAB	INJ-SC SOL	40MG
09857326	ADALIMUMAB	INJ-SC SOL	40MG
09857327	ADALIMUMAB	INJ-SC SOL	40MG
02130181	ALDESLEUKIN	IV PWS	1.3MG
02331675	CERTOLIZUMAB PEGOL	INJ-SC SOL	200MG/ML
09857394	ETANERCEPT RECOMBINANT	INJ SOL	50MG/ML
02242903	ETANERCEPT RECOMBINANT	INJ-SC PWS	25MG
02274728	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
09857322	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
02233014	GLATIRAMER	INJ-SC PWS	20MG
02245619	GLATIRAMER	INJ-SC SOL	20MG/ML
02324776	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02324784	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02244016	INFLIXIMAB	IV PWS	100MG
09852956	INFLIXIMAB	IV PWS	100MG
02419475	INFLIXIMAB	PWD VIAL	100MG
02239832	INTERFERON	INJ-SC SOL	0.03MG/ML
09852751	INTERFERON	OPH SOL	1MU/ML
02223384	INTERFERON ALFA 2B	INJ PWS	3MMU
02223392	INTERFERON ALFA 2B	INJ PWS	5MMU
02223406	INTERFERON ALFA 2B	INJ PWS	10MMU
02231651	INTERFERON ALFA 2B	INJ PWS	18MMU
00889067	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02223414	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02238674	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
02238675	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
09853995	INTERFERON ALFA 2B	INJ SOL	10MU/VIAL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength	
09854045	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML	
09854053	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML	
00705896	INTERFERON ALFA 2B	INJ-SC SOL	3MMU	
00705918	INTERFERON ALFA 2B	INJ-SC SOL	5MMU	
00705926	INTERFERON ALFA 2B	INJ-SC SOL	10MMU	
02240693	INTERFERON ALFA 2B	INJ-SC SOL	18MMU/1.2ML	
02240694	INTERFERON ALFA 2B	INJ-SC SOL	30MMU/1.2ML	
02240695	INTERFERON ALFA 2B	INJ-SC SOL	60MMU/1.2ML	
01911988	INTERFERON ALFA-2A	INJ PWS	3000MU/ML	
01911996	INTERFERON ALFA-2A	INJ PWS	9000MU/ML	
01912003	INTERFERON ALFA-2A	INJ PWS	6000MU/ML	
00812471	INTERFERON ALFA-2A	INJ PWS	6000MU/ML	
00812498	INTERFERON ALFA-2A	INJ SOL	6000MU/ML	
00812501	INTERFERON ALFA-2A	INJ SOL	3000MU/ML	
02217015	INTERFERON ALFA-2A	INJ SOL	3000MU/ML	
02217031	INTERFERON ALFA-2A	INJ SOL	6000MU/ML	
02217058	INTERFERON ALFA-2A	INJ SOL	9000MU/ML	
02217066	INTERFERON ALFA-2A	INJ SOL	18000MU/ML	
02019914	INTERFERON ALFA-2A	INJ SOL	9000MU/ML	
01959069	INTERFERON ALPHA-N1	INJ SOL	10MU	
01959077	INTERFERON ALPHA-N1	INJ SOL	3MU	
00709042	INTERFERON ALPHA-N1	INJ SOL	3MU	
00709050	INTERFERON ALPHA-N1	INJ SOL	10MU	
02169649	INTERFERON BETA	INJ-SC PWS	0.3MG	
02237317	INTERFERON BETA 1A	INJ PWS	11MCG	
02237318	INTERFERON BETA 1A	INJ PWS	44MCG	
02237770	INTERFERON BETA 1A	INJ-IM PWS	30MCG/1.1ML	
02269201	INTERFERON BETA 1A	INJ-IM SOL	30MCG/0.5ML	
02318253	INTERFERON BETA 1A	INJ-SC SOL	66MCG/1.5ML	
02318261	INTERFERON BETA 1A	INJ-SC SOL	132MCG/1.5ML	
02237319	INTERFERON BETA 1A	INJ-SC SOL	22MCG/0.5ML	
02237320	INTERFERON BETA 1A	INJ-SC SOL	44MCG/0.5ML	
09857395	INTERFERON BETA-1A	PREF AUTOINJ PEN	30MCG/0.5ML	
02337819	INTERFERON BETA-1B	RECOMBINANT	INJ-SC PWS	0.3MG
00846368	LEVAMISOLE HCL	TAB	50MG	
02234217	LEVAMISOLE HCL	TAB	50MG	
09857505	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248077	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248078	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/ML

DIN	Drug Name	Route of Administration	Strength
00258482	BLEOMYCIN SULFATE	INJ PWS	15U
00163899	DAUNORUBICIN HCL	INJ PD	20MG
01926683	DAUNORUBICIN HCL	IV PWS	20MG
00353078	DOXORUBICIN HCL	IV PWS	50MG
00357391	DOXORUBICIN HCL	IV PWS	10MG
00640050	EPIRUBICIN HCL	INJ PWS	10MG
00640069	EPIRUBICIN HCL	IV PWS	50MG
00381799	MITOMYCIN	IV PWS	5MG
00463221	MITOTANE	TAB	500MG
02415992	AFLIBERCEPT	VIAL	40MG/ML
02273993	ALEMTUZUMAB	IV SOL	10MG/ML
02290960	ALEMTUZUMAB	IV SOL	30MG/ML
02270994	BEVACIZUMAB	IV SOL	25MG/ML
09857407	RITUXIMAB	IV SOL	10MG/ML
02241927	RITUXIMAB	IV SOL	10MG/ML

**Appendix: ICD-9 codes and ICD-10 codes utilized to define acute respiratory illness in physician,
ER and hospital encounters.**

Description	ICD-9 Code	ICD-10 Code
Viral infection, unspecified site	079	B34
Viral agents as the cause of diseases classified to other chapters	--	B97 (but not B973 or B977)
Acute nasopharyngitis (common cold)	460	J00
Acute sinusitis	461	J01
Acute pharyngitis	462	J02
Acute tonsillitis	463	J03
Acute laryngitis, tracheitis, epiglottitis, croup	464	J04, J05
Acute upper respiratory infections of multiple or unspecified sites	465	J06
Influenza due to identified novel influenza A virus	488	J09
Influenza	487	J10, J11
Pneumonia, organism unspecified	486	--
Viral pneumonia	480	J12
Bacterial pneumonia	481, 482	J13, J14, J15
Pneumonia due to other specified organism	483	J16
Pneumonia in infectious diseases classified elsewhere	484	J17
Bronchopneumonia, organism unspecified	485	J18
Acute bronchitis and bronchiolitis	466	J20, J21
Unspecified diseases respiratory system	519	J22, J39.8, J39.9
Bronchitis, not specified as acute or chronic	490	J40
Acute respiratory distress syndrome	518.82	J80
Pulmonary edema	518.4	J81
Pleural effusion	510.9, 511.0, 511.1, 511.89	J86.9, J90, R09.1
Respiratory failure	518.81	J96.0, J96.9
Atelectasis	--	J98.10
Pulmonary collapse	518.0	J98.19
Other respiratory disorders	786.00, 786.09	J98.0, J98.4, J98.8, J98.9
Hemoptysis	786.30	R04.2
Cough	786.2	R05
Shortness of breath (dyspnea)	786.02, 786.05, 786.09	R06.0
Stridor	786.1	R06.1
Wheezing	786.07	R06.2
Tachypnea	786.06	R06.4

Description	ICD-9 Code	ICD-10 Code
Chest pain on breathing	786.52	R07.1
Hypoxemia	799.02	R09.0
Respiratory arrest	799.1	R09.2
Abnormal sputum	786.4	R09.3
Nasal congestion	478.19	R09.81
Abnormal chest sounds	786.7	R09.89
Fever	780.60	R50
Chills (without fever)	780.64	R68.0
Sepsis, shock	669.11, 669.12, 669.14, 785.50, 785.52, 995.91, 995.92	A41.9, R57.9

For peer review only

BMJ Open

Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029708.R3
Article Type:	Protocol
Date Submitted by the Author:	18-Jul-2019
Complete List of Authors:	Scott, Allison; Government of Alberta, Ministry of Health; PolicyWise for Children & Families Buchan, Sarah; Institute for Clinical Evaluative Sciences; Public Health Ontario Kwong, Jeff; Institute for Clinical Evaluative Sciences Drews, Steven; Alberta Provincial Laboratory for Public Health; University of Alberta, Division of Preventive Medicine Simmonds, Kimberley; Alberta Ministry of Health, Epidemiology and Surveillance Svenson, Lawrence; Government of Alberta, Ministry of Health; University of Calgary Cumming School of Medicine, Department of Community Health Sciences
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Public health, Epidemiology
Keywords:	Influenza, Vaccine effectiveness, Case Control, Test-negative, Administrative data, Population level

SCHOLARONE™
Manuscripts

1
2
3 1 **TITLE**

4
5 2 **Using population-wide administrative and laboratory data to estimate type- and subtype-specific**
6 3 **influenza vaccine effectiveness: a surveillance protocol**

7
8 4 Allison N Scott^{1,2,3}

9
10 5 Sarah A Buchan^{4,5,6}

11
12 6 Jeffrey C Kwong^{4,5,6,7,8}

13
14 7 Steven J Drews^{9,10}

15
16 8 Kimberley A Simmonds^{1,11}

17
18 9 Lawrence W Svenson^{1,11, 12, 13}

19
20 10

21
22 11 **Affiliations**

23
24 12 ¹Ministry of Health, Government of Alberta, Edmonton, AB, Canada

25
26 13 ²PolicyWise for Children & Families, Edmonton, AB, Canada

27
28 14 ³Department of Public Health, Concordia University of Edmonton, AB, Canada

29
30 15 ⁴ICES, Toronto, ON, Canada

31
32 16 ⁵Public Health Ontario, Toronto, ON, Canada

33
34 17 ⁶Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

35
36 18 ⁷Department of Family & Community Medicine, University of Toronto, Toronto, ON, Canada

37
38 19 ⁸University Health Network, Toronto, ON, Canada

39
40 20 ⁹The Alberta Provincial Laboratory for Public Health, Edmonton, AB, Canada

41
42 21 ¹⁰Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada

43
44 22 ¹¹ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary,
45 23 AB, Canada

46
47 24 ¹² School of Public Health, University of Alberta, Edmonton, AB, Canada

48
49 25 ¹³ Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada

50
51 26

52
53 27 **Corresponding Author:**

54
55 28 Allison N. Scott, Ph.D.

1
2
3 29 PolicyWise for Children & Families
4
5 30 1000, 9925-109 Street NW
6
7 31 Edmonton, Alberta, Canada T5K 2J8
8

9 32

10
11 33 **Email Addresses**

12
13 34 Allison N Scott AScott@policywise.com
14
15 35 Sarah A Buchan Sarah.Buchan@oahpp.ca
16
17 36 Jeffrey C Kwong jeff.kwong@utoronto.ca
18
19 37 Steven J Drews steven.drews@blood.ca
20
21 38 Kimberley A Simmonds kimberley.simmonds@gov.ab.ca
22
23 39 Lawrence W Svenson larry.svenson@gov.ab.ca
24

25 40

26
27 41

28
29 42 **Word Count:** 2,550
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **43 ABSTRACT**

4
5 **44 Introduction**

6
7 45 The appropriateness of using routinely collected laboratory data combined with administrative data for
8
9 46 estimating influenza vaccine effectiveness (VE) is still being explored. This paper outlines a protocol to
10
11 47 estimate influenza VE using linked laboratory and administrative data which could act as a companion to
12
13 48 estimates derived from other methods.

14
15
16 **49 Methods and Analysis**

17
18 50 We will use the test-negative design to estimate VE for each influenza type/subtype and season. Province-
19
20 51 wide individual-level records of positive and negative influenza tests at the Provincial Laboratory for Public
21
22 52 Health in Alberta will be linked, by unique personal health numbers, to administrative databases and
23
24 53 vaccination records held at the Ministry of Health in Alberta to determine covariates and influenza
25
26 54 vaccination status, respectively. Covariates of interests include age, sex, immunocompromising chronic
27
28 55 conditions, and healthcare setting. Cases will be defined based on an individual's first positive influenza test
29
30 56 during the season, and potential controls will be defined based on an individual's first negative influenza test
31
32 57 during the season. One control for each case will be randomly selected based on the week the specimen was
33
34 58 collected. We will estimate vaccine effectiveness using multivariable logistic regression.

35
36
37 **59 Ethics and Dissemination**

38
39 60 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
40
41 61 under study ID Pro00075997. Results will be disseminated by public health officials in Alberta.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 65 **Key Words**
4

5 66 Influenza
6

7 67 Vaccine effectiveness
8

9 68 Case Control
10

11 69 Test-negative
12

13 70 Administrative data
14

15 71 Population-level
16

17 72 Laboratory data
18

19 73 Vaccination database
20

21 74
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

75 **ARTICLE SUMMARY**

76 **Strengths and limitations of this study**

- 77 • A strength of this protocol is that it provides timely estimation of vaccine effectiveness to assist
78 public health in allocating resources and determining the appropriate policies and public messaging
79 during the influenza season.
- 80 • Vaccine effectiveness estimates use a test negative design, taking advantage of linked administrative
81 health records for the entire population.
- 82 • While many confounders are included in the vaccine effectiveness estimates, not all known
83 confounders can be measured using administrative health data.

84

For peer review only

85 INTRODUCTION

86 Influenza is a respiratory viral disease associated with significant morbidity and mortality globally. Infections
87 range from relatively mild presentations (e.g. cough, sore throat) to severe lower respiratory tract infections
88 (e.g. pneumonia). Severe cases may be associated with hospitalization, intensive care admission, and death;
89 young children, the elderly, and individuals with chronic conditions are at highest risk of severe outcomes[1].
90 In Canada, rates of laboratory-confirmed influenza infections are, on average, approximately 200 cases per
91 100,000 population, with approximately 50% of cases occurring in patients aged ≤ 18 years [2]. The causative
92 agents, influenza A (subtypes H3N2 and H1N1pdm(09)) and influenza B (Yamagata and Victoria lineages),
93 are under strong selective pressure to mutate genetically; significant genetic changes can occur in relatively
94 short periods of time (i.e. <1 year) [3].

95 Influenza prevention relies, in part, on annual vaccination campaigns. Selection of viral strains for inclusion
96 in the vaccine occurs approximately 9 months prior to the onset of the influenza season; by the time the
97 vaccines are administered, the predominant circulating strains may have mutated to the point such that the
98 effectiveness of the vaccine has diminished or has become completely ineffective [4,5].

99 Influenza VE is commonly estimated using the test-negative design, a variation of the case-control design
100 where cases and controls are selected from a pool of individuals who have been tested for influenza [6–10].
101 Several research groups use sentinel physician networks to recruit patients: influenza testing is performed on
102 patients who meet a case definition for influenza-like illness, and cases and controls are selected from that
103 pool [6–8]. While this has become an established method, there are some limitations to using sentinel
104 physicians. As the physicians are often volunteers, there can be bias in the geographic distribution, leading to
105 clustering of sampling in certain areas and not others. This can lead to inaccuracies as predominant
106 circulating influenza strains vary geographically [7,11]. Immunization information is commonly self-reported,
107 potentially leading to recall and social desirability biases [12]; volunteer physicians may be more likely to have
108 strong views on influenza immunization, potentially making it more difficult for the patient to admit to not
109 being immunized. Finally, as these studies are labour-intensive for clinic staff, physician recruitment is often

1
2
3 110 low, resulting in small sample sizes and wide confidence intervals. Estimates are, therefore, typically available
4
5 111 after the peak of the influenza season, decreasing their usefulness for public health messaging and resource
6
7 112 and operational planning [6–8,11].
8
9

10 113 Using administrative data and routinely collected clinical specimens for estimating VE is currently under
11
12 114 debate [13]. VE estimates generated using linked health administrative and laboratory data in the province
13
14 115 Ontario have been shown to be comparable to previously published estimates[14]. There has been one
15
16 116 published estimate of Alberta-specific vaccine effectiveness using a sentinel surveillance system[11]; however,
17
18 117 because of the small sample size the confidence interval was large, ranging from 8% to 72%. Estimating VE
19
20 118 in a large jurisdiction with near-real-time data on all influenza laboratory testing and influenza vaccination in
21
22 119 the population has the potential to provide more precise and timely VE estimates than has previously been
23
24 120 possible. We present a protocol to estimate influenza VE using individually-linked laboratory and
25
26 121 administrative data.
27
28

29
30 122

31 32 123 **METHODS AND ANALYSIS**

33 34 35 124 **Study Setting:**

36
37
38 125 Alberta is a province in Canada with a publicly-funded universal health care system; each of the 4.25 million
39
40 126 residents is assigned a unique personal health number (PHN) at birth or upon immigration to the province
41
42 127 [15]. The PHN is recorded each time a person accesses the healthcare system, allowing for deterministic
43
44 128 linkage across multiple administrative data sets held by the Ministry of Health.

45
46
47 129 In 2009, influenza vaccination became universally available to all Albertans aged ≥ 6 months, regardless of
48
49 130 comorbidities or other risk conditions [16]. Influenza vaccines are available at no cost to the patient at public
50
51 131 health clinics, pharmacies, physician offices, long-term care facilities, university health centers, and
52
53 132 workplaces. Annual vaccine campaigns begin in October, with approximately 60% of all influenza
54
55 133 vaccinations given by the end of the second week of the campaign. While the peak of influenza activity has
56
57

1
2
3 134 varied widely since 2010, the median influenza peak in Alberta is in mid-January, approximately three months
4
5 135 after the vaccination campaigns begin.
6
7

8 136

11 137 **Laboratory methods for influenza A and B detection and influenza A subtyping**

12
13 138 All influenza testing in Alberta is performed at a single diagnostic lab, the Provincial Laboratory for Public
14
15 139 Health (ProvLab) and stored in a single laboratory information system, along with test and patient identifiers.
16
17 140 Clinical specimens (e.g. nasopharyngeal swabs, nasopharyngeal aspirates, bronchoalveolar lavages) are
18
19 141 processed at ProvLab using previously published protocols. Nucleic acid extraction utilizes the easyMAG
20
21 142 extractor and reagents (bioMerieux, St. Laurent, Quebec, Canada)[17]. Nucleic acid from clinical specimens are
22
23 143 then tested using a series of respiratory detection assays as described below. Prior to May 2017, a real-time
24
25 144 influenza A/B reverse-transcriptase PCR (RT-PCR) was used to diagnose influenza using a protocol
26
27 145 previously described [18,19]. After May 2017, ProvLab has been using a Luminex Respiratory Pathogen Panel
28
29 146 for the identification of influenza A (including subtype), influenza B, and other respiratory viruses (e.g.
30
31 147 coronavirus and parainfluenza) [15]. Results of the laboratory testing were imported into specific laboratory
32
33 148 information systems depending on the testing time period.
34
35

36 149

38 150 **Study Design:**

39
40
41 151 We will use the test-negative design to estimate VE. We will estimate VE for the 2011/12 – 2019/20
42
43 152 influenza seasons. The results of all respiratory virus tests conducted at ProvLab will be sent to the Ministry
44
45 153 of Health for deterministic linkage to health administrative databases, in order to determine eligibility for
46
47 154 inclusion in the analysis, influenza vaccination status, and the following covariates: age, sex, socio-economic
48
49 155 status, geographic zone of residence, history of immunocompromising comorbidities, healthcare setting
50
51 156 (inpatient or outpatient setting), and month at the time of specimen submission. The presence of a diagnostic
52
53 157 code for an acute respiratory illness (ARI) at the time of specimen collection will be used in a sensitivity
54
55 158 analysis.
56
57
58
59
60

1
2
3 159 Isolates will be considered eligible for inclusion in the analysis if they met all of the following criteria: a valid
4
5 160 PHN is recorded, the isolate is not from a resident of a long-term care facility, the isolate was collected at
6
7 161 least four weeks after the initiation of the public influenza vaccination program, and the isolate was collected
8
9 162 during the influenza season, as determined using the method recommended by the WHO [20–22].

11
12 163 It is important to ensure that the population has the chance to be exposed to influenza and there is sufficient
13
14 164 time for immunity to the vaccine to be developed. Residence in a long-term care facility will be determined
15
16 165 via the Alberta Continuing Care Information System (ACCIS), which contains information on admissions
17
18 166 and discharges from long-term care facilities [23]. PHN validity will be assessed using the Alberta Health
19
20 167 Care Insurance Plan (AHCIP) Adjusted Population Registry, which contains records of all individuals
21
22 168 registered for healthcare insurance [23,24].

23
24
25 169 Individuals can have multiple laboratory tests over the course of their illness; therefore only the first positive
26
27 170 influenza test during the influenza season will be used, and potential control samples will be selected from
28
29 171 among those who only tested negative for influenza during that influenza season, using the first negative test.
30
31 172 Cases and controls tested <14 days after vaccination will be excluded from the analysis.

32
33
34 173 Influenza vaccination status will be determined from the Influenza Vaccination Registry. The registry
35
36 174 combines data from four databases that record influenza vaccination events (see below).

37
38
39 175 The following administrative data sets will be used in this study.

- 40
41
42 176
- 43 • Alberta Health Immunization and Adverse Reaction to Immunization system (Imm/ARI) contains
44 records of all publicly funded vaccines administered through public health, including influenza
45 177 vaccines administered at mass influenza vaccination clinics, public health clinics, and vaccinations
46 178 administered by public health nurses in long-term care facilities. Data submission is mandatory and
47 179 administered by public health nurses in long-term care facilities. Data submission is mandatory and
48 179 guidelines exist to support complete and accurate vaccination records with descriptions of each,
49 180 including notes [25,26].
50
51
52
53 181
- 54
55
56
57
58
59
60

- 1
2
3 182 • The Supplemental Enhanced Service Event (SESE) database captures physician claims for billing
4
5 183 purposes; International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes,
6
7 184 procedure codes (Canadian Classification of Procedures), codes indicating location of service
8
9 185 delivery, and a number of other administrative elements used to support the payment for each
10
11 186 patient encounter [24,27,28].
- 13
14 187 • Alberta Blue Cross (ABC) administers the pharmacist component of the universal vaccination
15
16 188 program. Pharmacists administering influenza vaccines through this program submit claims to ABC
17
18 189 for each vaccine provided; they are required to submit patient information such as PHN, date of
19
20 190 service, name, and address.
- 21
22 191 • The Pharmaceutical Information Network (PIN) database records dispensed pharmacological
23
24 192 products, regardless of payer, including the rare instances when an influenza vaccine is purchased
25
26 193 rather than administered through the public program (e.g. purchased by travelers prior to the launch
27
28 194 of the public campaign). PIN captures approximately 95% of all dispensed events in the province
29
30 195 [23].
- 31
32 196 • Provincial Vaccine Registry combines influenza vaccinations given in the province and recorded in
33
34 197 four source databases (PIN, ABC, SESE and Imm/ARI).
- 35
36 198 • Alberta Health Care Insurance Plan (AHCIP) Population Registry contains demographic variables,
37
38 199 age, sex, socio-economic status, and geographic zone of residence. Neighbourhood-level socio-
39
40 200 economic status is derived from census dissemination area income quintiles using postal code.
- 41
42 201 • Morbidity and Ambulatory Care Abstracting Reporting (MACAR) system contains ICD-10-CA
43
44 202 diagnostic codes, procedure codes, the date of admission, and date of discharge for every visit to
45
46 203 hospitals, emergency rooms, and outpatient clinics.

47
48
49
50 204 The quality of administrative datasets in Alberta has been extensively reviewed [29–31].

51
52
53 205 Individuals will be considered inpatients if they have at least one physician claim for inpatient services on
54
55 206 the same day as specimen collection or if specimen collection occurred during an inpatient stay; all others

1
2
3 207 will be considered outpatients. Individuals with an immunocompromising condition will be defined as
4
5 208 those who have a diagnosis of HIV, who received an organ transplant, or received oral corticosteroids
6
7 209 (for ≥ 30 days), antineoplastic agents, or another immunocompromising drug from a community
8
9 210 pharmacist in the past 6 months. (Appendix 1 and 2) [32]. HIV diagnosis and ARI will be determined
10
11 211 through physician claims and MACAR. Organ transplantation will be determined using MACAR, and
12
13 212 immunocompromising drug dispensations will be identified through PIN.

16 213 **Statistical Analysis**

19 214 Vaccine effectiveness data will be refreshed and the analysis completed every two weeks until the peak of the
20
21 215 influenza season and monthly thereafter. We will use multivariable logistic regression to estimate influenza
22
23 216 vaccine effectiveness as $(1 - \text{adjusted OR}) \times 100\%$ and will compare the results to historical values of VE for
24
25 217 the predominate subtype. We will estimate VE separately by influenza season and influenza subtype (i.e.,
26
27 218 A(H3N2), A(H1N1)pdm09, and influenza B) [33]. When there is a large enough sample size in a particular
28
29 219 season to provide adequate power, VE will be estimated for specific age groups such as children under the
30
31 220 age of 5 and seniors over the age of 65. The following covariates will be included in the adjusted model,
32
33 221 regardless of statistical significance: age, sex, socio-economic status, geographic zone of residence, history of
34
35 222 immunocompromising comorbidities, healthcare setting (inpatient or outpatient setting), and month of
36
37 223 specimen submission within the influenza season. SAS version 9.4 will be used for all statistical analysis (SAS
38
39 224 Institute Inc, Cary, NC). VE estimates will be compared to published estimates of VE [6,7,11,13,34,35].
40
41
42
43 225 As shedding of influenza virus continues for approximately 4-5 days after symptom onset, bias can result if
44
45 226 specimens that are collected too long after symptom onset are used [36]. Most studies use a threshold of 7
46
47 227 days [37]. To test the robustness of the findings, a sensitivity analysis will be performed; controls will be
48
49 228 restricted to those specimens positive for a different respiratory virus (i.e. coronavirus, human respiratory
50
51 229 syncytial virus) (As suggested by Sullivan et al 2016).

54 230 A potential limitation to this study is that the samples utilized here are clinical isolates taken through the
55
56 231 course of normal patient care, and are not from a standard case definition as is utilized in some other studies

1
2
3 232 [12]. To test the robustness of the findings, the analysis will be repeated using only cases and controls that
4
5 233 were given a diagnosis code for ARI on the same day as specimen collection, as per the SESE database or
6
7 234 MACAR. Appendix 3 lists the ICD-9 and ICD-10 codes used to define ARIs.
8
9

10 235

13 236 **PATIENT AND PUBLIC INVOLVEMENT**

16 237 Patients and the public were not involved in the design of the study, including the development of the
17
18 238 research question, outcomes measures, recruitment to or conduct of the study. The results of the study will
19
20 239 be disseminated to the public as deemed appropriate by public health officials.
21
22

23 240

26 241 **DISCUSSION**

28 242 This protocol describes the estimation of seasonal influenza VE using specimens collected for routine
29
30 243 influenza diagnostics as well as administrative data and vaccination records.
31
32

33 244 A key strength of this approach is the large sample size. This approach allows calculation of timely, precise
34
35 245 influenza VE estimates weeks prior to the influenza season peak, creating an early warning system for public
36
37 246 health if, as in the 2014-2015 season, the vaccine is found to have exceedingly low effectiveness. Early
38
39 247 notification of VE can assist public health in determining policies, messaging, and allocation of resources
40
41 248 (antiviral agents, staffing emergency departments) to counter a potentially more severe influenza season
42
43 249 [37,38]. The large sample size also allows for stratified analyses of VE based on product, age group, or region.

46 250 Whereas sentinel physician networks rely primarily on self-reported measures of influenza vaccination [34], a
47
48 251 significant strength of this study is the use of the near-real-time influenza vaccination registry that contains
49
50 252 individual-level, linkable data for most influenza vaccinations administered in the province. Use of this
51
52 253 registry reduces the likelihood of recall error and information biases such as social desirability bias and
53
54
55
56
57
58
59
60

1
2
3 254 reduces non-differential misclassification, which would bias the odds ratio towards the null, thus
4
5 255 underestimating VE [12].
6
7

8 256 Finally, we are certain to capture the results of all respiratory virus testing in the province, as all respiratory
9
10 257 virus testing is centralized at ProvLab and there is limited use of point-of-care testing.
11
12

13 258 There are some limitations to this methodology compared to the traditional method of VE estimation using
14
15 259 sentinel physician networks, because a standardized clinical case definition cannot be applied to determine
16
17 260 study eligibility. A sensitivity analysis restricting to healthcare encounters with a diagnosis code for ARI will
18
19 261 be used as a proxy for a standard case definition.
20
21

22 262 While the inclusion of confounders is important for VE estimate adjustment, not all known confounders can
23
24 263 be measured using administrative data. Frailty has been demonstrated to be a potential confounder of VE
25
26 264 [39–41]. Frailty cannot be included in the multivariable model because no validated indices of frailty
27
28 265 generated from standard administrative data exist at this time. However, this may not affect the results
29
30 266 significantly as a previous study indicated that inclusion of frailty in the multivariate model increased VE
31
32 267 estimates only slightly [42].
33
34

35 268 Laboratory requisitions in Alberta do not contain illness onset date. Ideally this would be used to ensure that
36
37 269 the negative laboratory test results were representative of an acute infectious period and that test-negative
38
39 270 specimens were not collected after viral shedding had ceased. Sullivan et al 2016 have indicated this bias may
40
41 271 be accounted for by selecting influenza test-negative controls that were positive for another respiratory virus.
42
43 272 Requiring controls to be positive for another virus excludes individuals who are tested long after their acute
44
45 273 infectious period. However, a recent systematic review found no differences when using different groups of
46
47 274 controls [43].
48
49

50
51 275 Comparison of the VE results using administrative data to previously published studies, specifically sentinel
52
53 276 surveillance for the same seasons (2011/12 – 2018/19) will help to identify further areas of refinement.
54
55
56
57
58
59
60

1
2
3 277 This approach could successfully allow for the generation of early influenza VE estimates which could
4
5 278 facilitate tailoring of public health messaging and assist in public health operations planning for the peak of
6
7 279 the influenza season.
8

9 280

11 281 **ETHICS**

13 282 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
14
15 283 under study ID Pro00075997.
16

17 284

19 285 **LIST OF ABBREVIATIONS**

21 286 ABC – Alberta Blue Cross

23 287 ACCIS – Alberta Continuing Care Information System

25 288 AHCIP – Alberta Health Care Insurance Plan Adjusted Population Registry

27 289 CCI – Canadian Classification of Health Interventions

29 290 CCP – Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures

31 291 ICD-9 – International Classification of Diseases, Ninth Revision

33 292 ICD-10 – International Classification of Diseases, Tenth Revision

35 293 Imm/ARI – Alberta Health Immunization and Adverse Reaction to Immunization system

37 294 MACAR – Morbidity and Ambulatory Care Abstracting Reporting

39 295 PHN – Personal Health Number

41 296 PIN – Pharmaceutical Information Network

43 297 ProvLab – Alberta Provincial Laboratory for Public Health

45 298 RT-PCR – Reverse Transcriptase Polymerase Chain Reaction

47 299 SESE – Supplemental Enhance Service Event

49 300 VE – Vaccine Effectiveness

51 301

53 302 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

1
2
3 303 Ethics approval was obtained from the University of Alberta's Health Research Ethics Board – Health Panel
4
5 304 under study ID Pro00075997.
6

7 305

8
9 306 **CONSENT FOR PUBLICATION**

10
11 307 Not applicable
12
13

14 308

15
16
17 309 **AVAILABILITY OF DATA AND MATERIALS**

18
19 310 Not applicable
20
21

22 311

23
24 312 **COMPETING INTERESTS**

25
26 313 The authors declare that they have no competing interests.
27
28

29 314

30
31 315 **FUNDING**

32
33 316 Not applicable
34
35

36 317

37
38 318 **AUTHOR STATEMENT**

39 319 ANS and SJD conceived of and designed the protocol and drafted and revised the manuscript. KS and LS
40 320 planned the original approach, providing guidance on available administrative database resources. SAB and
41 321 JCK made substantial contributions to the design and critically revised the manuscript.
42
43

44 322

45 323

46
47
48 324 **ACKNOWLEDGEMENTS**

49
50 325 The authors would like to acknowledge the staff at Alberta Health Services and ProvLab for their assistance
51 326 in providing administrative and laboratory data sources that could be implemented in this protocol.
52

53 327 **LICENCE STATEMENT**
54
55
56
57
58
59
60

1
2
3 328 * I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as
4 329 defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
5
6 330 contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence
7 331 shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or
8 332 employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free
9
10 333 basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by
11 334 BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and
12 335 to exploit all rights, as set out in our [licence](#).
13
14 336

15 337 The Submitting Author accepts and understands that any supply made under these terms is made by
16 338 BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a
17 339 postgraduate student of an affiliated institution which is paying any applicable article publishing charge
18 340 (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an
19 341 Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall
20 342 be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#)
21 343 licence will apply to this Work are set out in our licence referred to above.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

344 REFERENCES

- 345 1 Mertz D, Tae HK, Johnstone J, *et al.* Populations at risk for severe or complicated influenza illness:
346 systematic review and meta-analysis. *BMJ* 2013;**347**:10.
- 347 2 Alberta Health Services. Alberta Health Services. 2017.
- 348 3 Wong S-S, Webby RJ. Traditional and new influenza vaccines. *Clin Microbiol Rev* 2013;**26**:476–92.
349 doi:10.1128/CMR.00097-12
- 350 4 Skowronski DM, Chambers C, Sabaiduc S, *et al.* A Perfect Storm: Impact of Genomic Variation and
351 Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. *Clin Infect*
352 *Dis An Off Publ Infect Dis Soc Am* 2016;**63**:21–32. doi:10.1093/cid/ciw176
- 353 5 World Health Organization. Influenza Update N ° 309. 2018;**2018**:1–8.
- 354 6 Skowronski DM, De Serres G, Crowcroft NS, *et al.* Association between the 2008-09 seasonal
355 influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies
356 from Canada. *PLoS Med* 2010;**e1000258**. doi:10.1371/journal.pmed.1000258
- 357 7 Chambers C, Skowronski DM, Sabaiduc S, *et al.* Interim estimates of 2015/16 vaccine effectiveness
358 against influenza A(H1N1)pdm09, Canada, February 2016. *Euro Surveill Bull Eur Sur Les Mal Transm =*
359 *Eur Commun Dis Bull* 2016;**21**:30168. doi:10.2807/1560-7917.ES.2016.21.11.30168
- 360 8 Kwong JC, Campitelli MA, Gubbay JB, *et al.* Vaccine effectiveness against laboratory-confirmed
361 influenza hospitalizations among elderly adults during the 2010-2011 season. *Clin Infect Dis An Off Publ*
362 *Infect Dis Soc Am* 2013;**57**:820–7. doi:10.1093/cid/cit404
- 363 9 Orenstein WA, Bernier RH, Dondero TJ, *et al.* Field evaluation of vaccine efficacy. *Bull World Health*
364 *Organ* 1985;**63**:1055–68.
- 365 10 Public Health Agency of Canada. Effectiveness of Vaccine Against Medical Consultation Due to
366 Laboratory-Confirmed Influenza: Results From a Sentinel Physician Pilot Project in British Columbia,
367 2004-2005. *Can Commun Dis Rep* 2005;**31**:181–91.
- 368 11 Skowronski DM, Chambers C, Sabaiduc S, *et al.* Interim estimates of 2016/17 vaccine effectiveness
369 against influenza A(H3N2), Canada, January 2017. *Euro Surveill Bull Eur Sur Les Mal Transm = Eur*
370 *Commun Dis Bull* 2017;**22**. doi:10.2807/1560-7917.ES.2017.22.6.30460
- 371 12 World Health Organization (WHO). Evaluation of influenza vaccine effectiveness: A guide to the
372 design and interpretation of observational studies. 2017;**1**:1–47.
- 373 13 Belongia EA, Simpson MD, King JP, *et al.* Variable influenza vaccine effectiveness by subtype: a
374 systematic review and meta-analysis of test-negative design studies. *Lancet Infectious Dis* 2016;**16**:942–51.
375 doi:10.1016/S1473-3099(16)00129-8
- 376 14 Kwong JC, Buchan SA, Chung H, *et al.* Can routinely collected laboratory and health administrative
377 data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other
378 Respiratory Viruses Research (FOREVER) Cohort. *Vaccine* Published Online First: 17 June 2019.
379 doi:10.1016/j.vaccine.2019.06.011
- 380 15 Fathima S, Simmonds K, Invik J, *et al.* Use of laboratory and administrative data to understand the
381 potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in
382 Alberta, Canada. *BMC Infect Dis* 2016;**16**. doi:10.1186/s12879-016-1748-z

- 1
2
3 383 16 Government of Alberta. Alberta Health: History of immunization in Alberta. 2017.
4
5 384 17 Pabbaraju K, Tokaryk KL, Wong S, *et al*. Comparison of the luminex xTAG respiratory viral panel
6 385 with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. *J Clin*
7 386 *Microbiol* 2008;**46**:3056–62. doi:10.1128/JCM.00878-08
8
9 387 18 Pabbaraju K, Wong S, Wong AA, *et al*. Design and validation of real-time reverse transcription-PCR
10 388 assays for detection of pandemic (H1N1) 2009 virus. *J Clin Microbiol* 2009;**47**:3454–60.
11 389 doi:10.1128/JCM.01103-09
12
13 390 19 Chaudhry A, Bastien N, Li Y, *et al*. Oseltamivir resistance in an influenza A (H3N2) virus isolated
14 391 from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.
15 392 *Influenza Other Respi Viruses* 2016;**10**:532–5. doi:10.1111/irv.12415
16
17 393 20 World Health Organization. Global epidemiological surveillance standards for influenza. 2013.
18
19 394 21 World Health Organization. A Manual for Estimating Disease Burden Associated with Seasonal
20 395 Influenza. 2015.
21
22 396 22 Alberta Health. Alberta Health Seasonal Influenza in Alberta 2016/2017 Summary Report. 2017.
23
24 397 23 Government of Alberta. Overview of Administrative Health Datasets. 2017.
25
26 398 24 Russell ML, Schopflocher DP, Svenson L, *et al*. Secular trends in the epidemiology of shingles in
27 399 Alberta. *Epidemiol Infect* 2007;**135**:908–13.
28
29 400 25 Government of Alberta. Immunization data submission and response guidelines. 2017.
30
31 401 26 MacDonald SE, Dover DC, Simmonds KA, *et al*. Risk of febrile seizures after first dose of measles-
32 402 mumps-rubella- varicella vaccine: A population-based cohort study. *CMAJ* 2014;**186**:824–9.
33 403 doi:10.1503/cmaj.140078
34
35 404 27 Alberta Health. Alberta Health Claims Assessment.
36 405 2017. <https://open.alberta.ca/publications/alberta-health-diagnostic-codes> (accessed 23 Feb 2018).
37
38 406 28 Lix LM, Walker R, Quan H, *et al*. Features of physician services databases in Canada. *Chronic Dis Inj*
39 407 *Can* 2012;**32**:186–93.
40
41 408 29 Hinds A, Lix LM, Smith M, *et al*. Quality of administrative health databases in Canada: a scoping
42 409 review. *Can J Public Heal* 2016;**107**:e56--e61.
43
44 410 30 Shiff NJ, Jama S, Boden C, *et al*. Validation of administrative health data for the pediatric population:
45 411 A scoping review. *BMC Health Serv Res* 2014;**14**. doi:10.1186/1472-6963-14-236
46
47 412 31 Quan H, Smith M, Bartlett-Esquilant G, *et al*. Mining Administrative Health Databases to Advance
48 413 Medical Science: Geographical Considerations and Untapped Potential in Canada. *Can J Cardiol*
49 414 2012;**28**:152–4. doi:10.1016/j.cjca.2012.01.005
50
51 415 32 Schwartz KL, Jembere N, Campitelli MA, *et al*. Using physician billing claims from the Ontario Health
52 416 Insurance Plan to determine individual influenza vaccination status: an updated validation study. *C*
53 417 *Open* 2016;**4**:E470.
54
55 418 33 Sullivan SG, Cowling BJ. ‘Crude Vaccine Effectiveness’ Is a Misleading Term in Test-negative Studies
56 419 of Influenza Vaccine Effectiveness. *Epidemiology* 2015;**26**:e60. doi:10.1097/EDE.0000000000000343
57
58
59
60

- 1
2
3 420 34 Skowronski DM, Janjua NZ, De Serres G, *et al.* Low 2012-13 influenza vaccine effectiveness
4 421 associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating
5 422 viruses. *PLoS One* 2014;**9**:e92153. doi:10.1371/journal.pone.0092153
6
7 423 35 Skowronski DM, Chambers C, Sabaiduc S, *et al.* Interim estimates of 2013/14 vaccine effectiveness
8 424 against influenza A(H1N1)PDM09 from Canada's sentinel surveillance network, January 2014.
9 425 *Eurosurveillance* 2014;**19**.
10
11 426 36 Sullivan SG, Tchetgen Tchetgen J. E, Cowling BJ. Theoretical Basis of the Test-Negative Study
12 427 Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016;**184**:345–53.
13 428 doi:10.1093/aje/kww064
14
15 429 37 Orton L, Lloyd-Williams F, Taylor-Robinson D, *et al.* The use of research evidence in public health
16 430 decision making processes: systematic review. *PLoS One*;e21704. doi:10.1371/journal.pone.0021704
17
18 431 38 Savel TG, Foldy S. The role of public health informatics in enhancing public health surveillance.
19 432 *MMWR Suppl* 2012;**61**:20–4.
20
21 433 39 Nelson JC, Jackson ML, Weiss NS, *et al.* New strategies are needed to improve the accuracy of
22 434 influenza vaccine effectiveness estimates among seniors. *J Clin Epidemiol* 2009;**62**:687–94.
23 435 doi:10.1016/j.jclinepi.2008.06.014
24
25 436 40 Jackson LA, Jackson ML, Nelson JC, *et al.* Evidence of bias in estimates of influenza vaccine
26 437 effectiveness in seniors. *Int J Epidemiol* 2006;**35**:337–
27 438 44.[http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
28 439 [=true&db=cmedm&AN=16368725&site=eds-live&scope=site](http://login.ezproxy.library.ualberta.ca/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16368725&site=eds-live&scope=site)
29
30 440 41 Jackson LA, Nelson JC, Benson P, *et al.* Functional status is a confounder of the association of
31 441 influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol* 2006;**35**:345–52.
32
33 442 42 Talbot HK, Nian H, Chen Q, *et al.* Evaluating the case-positive, control test-negative study design for
34 443 influenza vaccine effectiveness for the frailty bias. *Vaccine* 2016;**34**:1806–9.
35 444 doi:10.1016/j.vaccine.2016.02.037
36
37 445 43 Feng S, Cowling BJ, Kelly H, *et al.* Estimating Influenza Vaccine Effectiveness With the Test-
38 446 Negative Design Using Alternative Control Groups: A Systematic Review and Meta-Analysis. *Am J*
39 447 *Epidemiol* 2018;**187**:389–97. doi:10.1093/aje/kwx251
40
41 448
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary File - Using population-wide administrative and laboratory data to estimate type-
and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Appendix: List of CCP, CCI, and CMG codes utilized to define individuals who have had an organ
transplant

CCP Code Description

495	Heart Transplantation
455	Lung Transplant
456	Combined Heart-Lung Transplantation
624	Liver Transplant
675	Transplant of Kidney
648	Transplant of Pancreas

CCI Code Description

1HY85	Transplant, Heart With Lung(S)
1HZ85	Transplant, Heart Nec
1GT85	Transplant, Lung Nec
1GR85	Transplant, Lobe of Lung
1OA85	Transplant, Liver
1PC85	Transplant, Kidney
1OJ85	Transplant, Pancreas
1OK85	Transplant, Pancreas With Duodenum
1NK85	Transplant, Small Intestine
1NP85	Transplant, Small And Large Intestine

CMG 1992 To 2005

175	Heart or Lung Transplant
253	Major Intestinal And Rectal Procedures
310	Liver Transplant
311	Major Pancreatic Procedures
500	Kidney Transplant

CMG 2007 To 2016

110	Lung Transplant
160	Heart Transplant
220	Major Upper Gastrointestinal Reconstruction/Excision
270	Liver/Pancreas/Duodenum Transplant
450	Kidney Transplant

1
2
3 **Appendix: List of drug names and DINs utilized to define immunocompromising conditions**
4
5

DIN	Drug Name	Route of Administration	Strength
00616192	ETOPOSIDE	CAP	50MG
00523410	ETOPOSIDE	IV SOL	20MG/ML
02080036	ETOPOSIDE	IV SOL	20MG/ML
02241182	ETOPOSIDE	IV SOL	20MG/ML
02231622	IRINOTECAN HCL	IV SOL	20MG/ML
02258218	IRINOTECAN HCL	IV SOL	20MG/ML
00015431	VINBLASTINE SULFATE	IV PWS	1MG/ML
00611182	VINCRISTINE SULFATE	IV SOL	1MG/ML
02143305	VINCRISTINE SULFATE	IV SOL	1MG/ML
00004618	BUSULFAN	TAB	2MG
00297763	CARMUSTINE	IV PWS	100MG
09851399	CARMUSTINE	TOP SOL	NOT AVLE
00004626	CHLORAMBUCIL	TAB	2MG
00344915	CYCLOPHOSPHAMIDE	INJ PWS	2GM
00013544	CYCLOPHOSPHAMIDE	IV PWS	200MG
00013552	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241797	CYCLOPHOSPHAMIDE	IV PWS	200MG
02241799	CYCLOPHOSPHAMIDE	IV PWS	1000MG
00013749	CYCLOPHOSPHAMIDE	TAB	50MG
00262676	CYCLOPHOSPHAMIDE	TAB	25MG
00344877	CYCLOPHOSPHAMIDE	TAB	25MG
00344885	CYCLOPHOSPHAMIDE	TAB	50MG
02241795	CYCLOPHOSPHAMIDE	TAB	25MG
02241796	CYCLOPHOSPHAMIDE	TAB	50MG
02063794	ESTRAMUSTINE DISODIUM PHOSPHATE	CAP	140MG
00780278	ESTRAMUSTINE PHOSPHATE	CAP	140MG
00360414	LOMUSTINE	CAP	100MG
00360422	LOMUSTINE	CAP	40MG
00360430	LOMUSTINE	CAP	10MG
00016063	MECHLORETHAMINE	IV PWS	10MG
00004715	MELPHALAN	TAB	2MG
02312794	TEMOZOLOMIDE	CAP	140MG
02312816	TEMOZOLOMIDE	CAP	180MG
02395274	TEMOZOLOMIDE	CAP	20MG
02395282	TEMOZOLOMIDE	CAP	100MG
02395290	TEMOZOLOMIDE	CAP	140MG
02395312	TEMOZOLOMIDE	CAP	250MG
02443473	TEMOZOLOMIDE	CAP	5MG
02443481	TEMOZOLOMIDE	CAP	20MG

DIN	Drug Name	Route of Administration	Strength
02443511	TEMOZOLOMIDE	CAP	100MG
02443538	TEMOZOLOMIDE	CAP	140MG
02443554	TEMOZOLOMIDE	CAP	250MG
02241093	TEMOZOLOMIDE	CAP	5MG
02241094	TEMOZOLOMIDE	CAP	20MG
02241095	TEMOZOLOMIDE	CAP	100MG
02241096	TEMOZOLOMIDE	CAP	250MG
02441160	TEMOZOLOMIDE	CAPSULE	5MG
00237035	THIOTEPA	INJ PWS	15MG/ML
02421917	CAPECITABINE	FC TAB	150MG
02421925	CAPECITABINE	FC TAB	500MG
02426757	CAPECITABINE	FC TAB	150MG
02426765	CAPECITABINE	FC TAB	500MG
02400022	CAPECITABINE	TAB	150MG
02400030	CAPECITABINE	TAB	500MG
02238453	CAPECITABINE	TAB	150MG
02238454	CAPECITABINE	TAB	500MG
02022117	CLADRIBINE	IV SOL	1MG
00194727	CYTARABINE	INJ PWS	500MG
00386715	CYTARABINE	INJ PWS	100MG
02167867	CYTARABINE	INJ PWS	100MG
00646296	CYTARABINE	IV PWS	1GM
00646318	CYTARABINE	IV PWS	2GM
02246226	FLUDARABINE PHOSPHATE	TAB	10MG
00012882	FLUOROURACIL	IV SOL	
00330582	FLUOROURACIL	TOP CRM	5%
00465283	HYDROXYUREA	CAP	500MG
02242920	HYDROXYUREA	CAP	500MG
02247937	HYDROXYUREA	CAP	500MG
00004723	MERCAPTOPURINE	TAB	50MG
02415275	MERCAPTOPURINE	TABLET	50MG
09857520	METHOTREXATE	INJ SOL	50MG/2ML
02182777	METHOTREXATE	INJ SOL	25MG/ML
02182955	METHOTREXATE	INJ SOL	25MG/ML
00014915	METHOTREXATE	TAB	2.5MG
02170698	METHOTREXATE	TAB	2.5MG
02182750	METHOTREXATE	TAB	10MG
02182963	METHOTREXATE	TAB	2.5MG
02244798	METHOTREXATE	TAB	2.5MG
02398427	METHOTREXATE	VIAL	25MG/ML
00321397	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
00321400	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength
02170663	METHOTREXATE DISODIUM	INJ SOL	50MG/2ML
02170671	METHOTREXATE DISODIUM	INJ SOL	2.5MG/ML
02182947	METHOTREXATE SODIUM	INJ SOL	10MG/ML
00614335	METHOTREXATE SODIUM	IV SOL	10MG/ML
00874132	METHOTREXATE SODIUM	TAB	2.5MG
02171767	METHOTREXATE SODIUM	TAB	2.5MG
00282081	THIOGUANINE	TAB	40MG
02384256	CRIZOTINIB	CAP	200MG
02384264	CRIZOTINIB	CAP	250MG
02409607	DABRAFENIB	CAP	50MG
02409615	DABRAFENIB	CAP	75MG
02320193	DASATINIB	TAB	100MG
02293129	DASATINIB	TAB	20MG
02293137	DASATINIB	TAB	50MG
02293145	DASATINIB	TAB	70MG
02269007	ERLOTINIB HCL	TAB	25MG
02269015	ERLOTINIB HCL	TAB	100MG
02269023	ERLOTINIB HCL	TAB	150MG
02377705	ERLOTINIB HCL	TABLET	100MG
02377713	ERLOTINIB HCL	TABLET	150MG
02434407	IBRUTINIB	CAP	140MG
09857447	IMATINIB MESYLATE	TAB	100MG
02388006	RUXOLITINIB	TAB	5MG
02388014	RUXOLITINIB	TAB	15MG
02388022	RUXOLITINIB	TAB	20MG
02409658	TRAMETINIB RECOMBINANT	TAB	2MG
01926438	ASPARAGINASE	INJ PWS	10MU
02389649	AXITINIB	TAB	5MG
02389630	AXITINIB	TAB FC	1MG
02262452	BORTEZOMIB	IV PWS	3.5MG
00521183	DACARBAZINE	IV PWS	200MG/VIAL
02154854	DACARBAZINE	IV PWS	200MG
02248676	GEFITINIB	TAB	250MG
02244725	IMATINIB MESYLATE	CAP	100MG
02399806	IMATINIB MESYLATE	FC TAB	100MG
02355337	IMATINIB MESYLATE	TAB	100MG
02355345	IMATINIB MESYLATE	TAB	400MG
02397285	IMATINIB MESYLATE	TAB	100MG
02397293	IMATINIB MESYLATE	TAB	400MG
02399814	IMATINIB MESYLATE	TAB	400MG
02431114	IMATINIB MESYLATE	TAB	100MG
02431122	IMATINIB MESYLATE	TAB	400MG

DIN	Drug Name	Route of Administration	Strength
09857448	IMATINIB MESYLATE	TAB	400MG
02253275	IMATINIB MESYLATE	TAB	100MG
02253283	IMATINIB MESYLATE	TAB	400MG
02326442	LAPATINIB DITOSYLATE	TAB	250MG
02315874	NILOTINIB	CAP	200MG
02368250	NILOTINIB	CAP	150MG
02352303	PAZOPANIB HCL	TAB	200MG
00012750	PROCARBAZINE HCL	CAP	50MG
02403390	REGORAFENIB	TAB	40MG
02284227	SORAFENIB TOSYLATE	TAB	200MG
02280795	SUNITINIB MALATE	CAP	12.5MG
02280809	SUNITINIB MALATE	CAP	25MG
02280817	SUNITINIB MALATE	CAP	50MG
02258595	ADALIMUMAB	INJ-SC SOL	40MG
09854785	ADALIMUMAB	INJ-SC SOL	40MG
09857294	ADALIMUMAB	INJ-SC SOL	40MG
09857326	ADALIMUMAB	INJ-SC SOL	40MG
09857327	ADALIMUMAB	INJ-SC SOL	40MG
02130181	ALDESLEUKIN	IV PWS	1.3MG
02331675	CERTOLIZUMAB PEGOL	INJ-SC SOL	200MG/ML
09857394	ETANERCEPT RECOMBINANT	INJ SOL	50MG/ML
02242903	ETANERCEPT RECOMBINANT	INJ-SC PWS	25MG
02274728	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
09857322	ETANERCEPT RECOMBINANT	INJ-SC SOL	50MG/ML
02233014	GLATIRAMER	INJ-SC PWS	20MG
02245619	GLATIRAMER	INJ-SC SOL	20MG/ML
02324776	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02324784	GOLIMUMAB RECOMBINANT	INJ-SC SOL	50MG/0.5ML
02244016	INFLIXIMAB	IV PWS	100MG
09852956	INFLIXIMAB	IV PWS	100MG
02419475	INFLIXIMAB	PWD VIAL	100MG
02239832	INTERFERON	INJ-SC SOL	0.03MG/ML
09852751	INTERFERON	OPH SOL	1MU/ML
02223384	INTERFERON ALFA 2B	INJ PWS	3MMU
02223392	INTERFERON ALFA 2B	INJ PWS	5MMU
02223406	INTERFERON ALFA 2B	INJ PWS	10MMU
02231651	INTERFERON ALFA 2B	INJ PWS	18MMU
00889067	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02223414	INTERFERON ALFA 2B	INJ SOL	10MMU/2ML
02238674	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML
02238675	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML
09853995	INTERFERON ALFA 2B	INJ SOL	10MU/VIAL

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DIN	Drug Name	Route of Administration	Strength	
09854045	INTERFERON ALFA 2B	INJ SOL	3MMU/0.5ML	
09854053	INTERFERON ALFA 2B	INJ SOL	5MMU/0.5ML	
00705896	INTERFERON ALFA 2B	INJ-SC SOL	3MMU	
00705918	INTERFERON ALFA 2B	INJ-SC SOL	5MMU	
00705926	INTERFERON ALFA 2B	INJ-SC SOL	10MMU	
02240693	INTERFERON ALFA 2B	INJ-SC SOL	18MMU/1.2ML	
02240694	INTERFERON ALFA 2B	INJ-SC SOL	30MMU/1.2ML	
02240695	INTERFERON ALFA 2B	INJ-SC SOL	60MMU/1.2ML	
01911988	INTERFERON ALFA-2A	INJ PWS	3000MU/ML	
01911996	INTERFERON ALFA-2A	INJ PWS	9000MU/ML	
01912003	INTERFERON ALFA-2A	INJ PWS	6000MU/ML	
00812471	INTERFERON ALFA-2A	INJ PWS	6000MU/ML	
00812498	INTERFERON ALFA-2A	INJ SOL	6000MU/ML	
00812501	INTERFERON ALFA-2A	INJ SOL	3000MU/ML	
02217015	INTERFERON ALFA-2A	INJ SOL	3000MU/ML	
02217031	INTERFERON ALFA-2A	INJ SOL	6000MU/ML	
02217058	INTERFERON ALFA-2A	INJ SOL	9000MU/ML	
02217066	INTERFERON ALFA-2A	INJ SOL	18000MU/ML	
02019914	INTERFERON ALFA-2A	INJ SOL	9000MU/ML	
01959069	INTERFERON ALPHA-N1	INJ SOL	10MU	
01959077	INTERFERON ALPHA-N1	INJ SOL	3MU	
00709042	INTERFERON ALPHA-N1	INJ SOL	3MU	
00709050	INTERFERON ALPHA-N1	INJ SOL	10MU	
02169649	INTERFERON BETA	INJ-SC PWS	0.3MG	
02237317	INTERFERON BETA 1A	INJ PWS	11MCG	
02237318	INTERFERON BETA 1A	INJ PWS	44MCG	
02237770	INTERFERON BETA 1A	INJ-IM PWS	30MCG/1.1ML	
02269201	INTERFERON BETA 1A	INJ-IM SOL	30MCG/0.5ML	
02318253	INTERFERON BETA 1A	INJ-SC SOL	66MCG/1.5ML	
02318261	INTERFERON BETA 1A	INJ-SC SOL	132MCG/1.5ML	
02237319	INTERFERON BETA 1A	INJ-SC SOL	22MCG/0.5ML	
02237320	INTERFERON BETA 1A	INJ-SC SOL	44MCG/0.5ML	
09857395	INTERFERON BETA-1A	PREF AUTOINJ PEN	30MCG/0.5ML	
02337819	INTERFERON BETA-1B	RECOMBINANT	INJ-SC PWS	0.3MG
00846368	LEVAMISOLE HCL	TAB	50MG	
02234217	LEVAMISOLE HCL	TAB	50MG	
09857505	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248077	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/0.5ML
02248078	PEGINTERFERON ALFA 2A	RECOMBINANT	INJ-SC SOL	180MCG/ML

DIN	Drug Name	Route of Administration	Strength
00258482	BLEOMYCIN SULFATE	INJ PWS	15U
00163899	DAUNORUBICIN HCL	INJ PD	20MG
01926683	DAUNORUBICIN HCL	IV PWS	20MG
00353078	DOXORUBICIN HCL	IV PWS	50MG
00357391	DOXORUBICIN HCL	IV PWS	10MG
00640050	EPIRUBICIN HCL	INJ PWS	10MG
00640069	EPIRUBICIN HCL	IV PWS	50MG
00381799	MITOMYCIN	IV PWS	5MG
00463221	MITOTANE	TAB	500MG
02415992	AFLIBERCEPT	VIAL	40MG/ML
02273993	ALEMTUZUMAB	IV SOL	10MG/ML
02290960	ALEMTUZUMAB	IV SOL	30MG/ML
02270994	BEVACIZUMAB	IV SOL	25MG/ML
09857407	RITUXIMAB	IV SOL	10MG/ML
02241927	RITUXIMAB	IV SOL	10MG/ML

**Appendix: ICD-9 codes and ICD-10 codes utilized to define acute respiratory illness in physician,
ER and hospital encounters.**

Description	ICD-9 Code	ICD-10 Code
Viral infection, unspecified site	079	B34
Viral agents as the cause of diseases classified to other chapters	--	B97 (but not B973 or B977)
Acute nasopharyngitis (common cold)	460	J00
Acute sinusitis	461	J01
Acute pharyngitis	462	J02
Acute tonsillitis	463	J03
Acute laryngitis, tracheitis, epiglottitis, croup	464	J04, J05
Acute upper respiratory infections of multiple or unspecified sites	465	J06
Influenza due to identified novel influenza A virus	488	J09
Influenza	487	J10, J11
Pneumonia, organism unspecified	486	--
Viral pneumonia	480	J12
Bacterial pneumonia	481, 482	J13, J14, J15
Pneumonia due to other specified organism	483	J16
Pneumonia in infectious diseases classified elsewhere	484	J17
Bronchopneumonia, organism unspecified	485	J18
Acute bronchitis and bronchiolitis	466	J20, J21
Unspecified diseases respiratory system	519	J22, J39.8, J39.9
Bronchitis, not specified as acute or chronic	490	J40
Acute respiratory distress syndrome	518.82	J80
Pulmonary edema	518.4	J81
Pleural effusion	510.9, 511.0, 511.1, 511.89	J86.9, J90, R09.1
Respiratory failure	518.81	J96.0, J96.9
Atelectasis	--	J98.10
Pulmonary collapse	518.0	J98.19
Other respiratory disorders	786.00, 786.09	J98.0, J98.4, J98.8, J98.9
Hemoptysis	786.30	R04.2
Cough	786.2	R05
Shortness of breath (dyspnea)	786.02, 786.05, 786.09	R06.0
Stridor	786.1	R06.1
Wheezing	786.07	R06.2
Tachypnea	786.06	R06.4

Description	ICD-9 Code	ICD-10 Code
Chest pain on breathing	786.52	R07.1
Hypoxemia	799.02	R09.0
Respiratory arrest	799.1	R09.2
Abnormal sputum	786.4	R09.3
Nasal congestion	478.19	R09.81
Abnormal chest sounds	786.7	R09.89
Fever	780.60	R50
Chills (without fever)	780.64	R68.0
Sepsis, shock	669.11, 669.12, 669.14, 785.50, 785.52, 995.91, 995.92	A41.9, R57.9

For peer review only